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ABSTRACT 
 
Over the centuries people have developed different forms of addiction to various 
substances. 
Drug addiction manifests clinically as compulsive drug seeking, drug use, and cravings 
that can persist and recur even after extended periods of abstinence. From a 
psychological and neurological perspective, addiction is a disorder of altered cognition.  
The brain regions and processes that underlie addiction overlap extensively with those 
that are involved in essential cognitive functions, including learning, memory, attention, 
reasoning, and impulse control.  Drugs alter normal brain structure and function in these 
regions, producing cognitive shifts that promote continued drug use through 
maladaptive learning and hinder the acquisition of adaptive behaviors that support 
abstinence. 
All addictive drugs have in common that they enhance (directly or indirectly or even 
trans synaptically) dopaminergic reward synaptic function in the nucleus accumbens 
(NA) and for this reason are used self-administration’s drugs  to maintain a high level of 
dopamine (DA) and thus a high level of hedonic. In some classes of addictive drugs 
(e.g. opiates), the tolerance to the euphoric effects develops with chronic use. 
The fundamental principle that unites addictive drugs is that each one enhances synaptic 
DA by means that dissociate it from normal behavioral control, so that they act to 
reinforce their own acquisition.  
Within this context, our attention has focused on the study of phenomena associated 
with the consumption of alcohol and heroin. 
Alcohol is the drug of abuse certainly more socially accepted and alcoholism, a 
condition that occurs following chronic use of alcohol, is the cause of many deaths. 
To figure out what dose would be most suitable for the treatment we began our studies 
by analyzing the blood alcohol levels (BALs), and also to understand which binge 
alcohol paradigm was chosen to more closely resemble human drinking behaviour. 
The data showed that single or repeated EtOH binge intoxication induce BALs in the 
range of 350–450 mg/dl and thus it was clearly pharmacologically active. During binge 
treatment, the highest BAL (450 mg/dl) was reached after 30 minutes following the 
third administration and decreased to the level 120 mg/ml after 9 hours. A single dose 
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caused a BAL of 350 mg/dl 1 hour after the administration and decreased to non-
pharmacologically level after 9 hours . 
After determining the time required to reach the highest levels of alcohol in the blood, 
the animals received daily intragastric administrations of alcohol (20% in water) at a 
dose of 1.5 g/kg or equal volume of water in their home cages following this binge 
pattern regimen: three times daily at 1.5-hour intervals (10:00 am, 11:30 am, and 1:00 
pm), for a total daily dose of 4.5 g/kg/day. They were sacrificed at different time point.  
 
• 1 day group (1D) treated for 1 day and sacrificed 24h after last administration 
• 5 days group (5D) treated for 5 days and sacrificed 24h after last administration 
• 1-WD treated for 5 day and maintained 24h in withdrawal, then sacrificed 
• 3-WD treated for 5 day and maintained for 3 days in withdrawal, then sacrificed 
• 7-WD treated for 5 day and maintained for 3 days in withdrawal, then sacrificed 
 
 
Behavioral observations of intoxication and withdrawal were carried out on the animals, 
under acohol exposure, by two operators independently and in blind fashion. 
EtOH-induced intoxication in animals starting from the first binge administration and 
reached the maximum peak at Day 2. Intoxication signs decreased over Day 3 and 
disappeared over Day 5. 
EtOH-treated rats showed significant withdrawal signs measured 20 hours after each 
final daily EtOH treatment. The sum of  the observation scores progressively increased 
from 0 on Day 1 to 12.5 ± 0.4 on Day with significant differences between the 
experimental groups on Day 4, Day 7, Day 9 and Day 10 confirming the presence of 
significant overall withdrawal severity. 
Although alcohol has long been considered an unspecific pharmacological agent, recent 
molecular pharmacology studies have shown that acts on different primary targets, 
including ion channels and receptors, kicking off a cascade of synaptic events involving 
many neurotransmitter systems.  
Through gene expression studies conducted in recent years, it has been shown that the 
classical opioid receptors are differently involved in the consumption of ethanol  and, 
furthermore, the system nociceptin / NOP, recently included in the family of 
endogenous opioid system, and both appear able to play a key role in the initiation of 
alcohol use in rodents. What emerges is that manipulation of the opioid system, 
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nociceptin in particular, may be useful in the treatment of addictions and there are 
several evidences that support the use of this strategy. The PFCx  is a region of especial 
interest in opiate addiction because it plays an important role in cognitive control over 
drug intake, and also because it is directly related with the meso-corticolimbic 
dopaminergic system that mediates the rewarding and addictive properties of opiates. 
Based on these informations we have performed our studies of gene expression to 
evaluate if the same experimental conditions could lead changes in another brain area. 
The second area studied was the AM, which is a major substrate for neuronal behavior 
associated with the consumption of alcohol and anxiety. 
In the AM, gene expression studies revealed a significant increase in the levels of 
PDYN in the group of animals treated for 1 day and in the W-1D group. In the PFCx 
after 1 day of treatment with EtOH, PDYN mRNA was increased, whereas no changes 
were evident in the other groups. 
In the AM levels of the PNOC mRNA transcript in the AM were significantly increased 
in the 1D group and continues to increase with the progression of the treatment (5D 
group) becoming even higher. When the animals were kept in abstinence, the levels of 
peptide mRNA were still significant high in theW-1D group. Conversely, in the PFCx 
we did not observe significant changes in the expression of PNOC. 
Alterations in the expression of the receptors are visible only for the receptor KOP in 
the AM area in 5D group; no alteration are visible in the PFCx for both receptors 
analyzed. Recently, an increasing number of experimental evidence suggest that 
changes in gene expression induced by drugs of abuse may be mediated by epigenetic 
mechanisms. 
It is already known that many histone modification act like marker to identify active/ or 
inactive chromatin structure in the regulation of gene transcription. 
In our study we used H3K27me3 which is a repressive marker; H3K9Ac and H3K4me3 
which are active marker. In the AM, we found in 1D group of animals a significant 
decrease of H3K27me3 in both PDYN and PNOC promoter regions as well as a 
significant increase in H3K9Ac for PDYN promoter and for PNOC promoter. In the 
AM of animals treated for 5 days (5D group) a significant  increase of H3K9Ac in 
PNOC promoter but no significant alteration we for other histone modification analyzed 
and in PDYN promoter region were found. In the AM, in contrast, we did not observe 
any histone modifications changes in the W-1D group in both genes promoter. 
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Moreover, EtOH exposure did not induce any statistically significant alteration of 
H3K27me3, H3K9ac and H3K4me3. 
The analyses of DNA methylation in PDYN and PNOC promoters didn’t show a 
significative alteration. 
The data, about alcohol exposure, confirm a role of the PDYN/KOP system in the 
negative hedonic state associated with alcohol addiction and the hypothesis that the 
NOC system could function as a ‘brake’ to limit EtOH intake. 
The linkage between gene expression alterations and epigenetic modulation in PDYN 
and PNOC promoters following alcohol treatment confirm the possible chromatin 
remodeling mechanism already proposed for alcoholism. 
Our results could be important to partially fill the lack of knowledge of how EtOH by 
itself affects the opioid system in the brain, and suggest the possibility of using drugs 
acting on these systems for the treatment of withdrawal symptoms and alcohol 
dependence. 
In the second part of present study, we also investigated alterations in signaling 
molecules directly associated with MAPK pathway in a unique collection of 
postmortem brains from heroin abusers.  
Several studies have implicated ERK1/2 and p38 MAPKs in the modulation of various 
forms of synaptic plasticity, including the neuroplastic changes induced by drugs of 
abuse. In addition to PKA-mediated protein phosphorylation, extracellular signal-
regulated kinase (ERK) activity may also be regulated after heroin exposure. Moreover, 
previous studies has shown that amphetamine activates extracellular signal-regulated 
kinase 1 and 2 (ERK1/2) resulting in cAMP response element-binding protein (CREB) 
and Elk-1 phosphorylation in striatal neurons. 
On basis of these findings, our interest was focused on understanding the effects that 
prolonged exposure of heroin can cause in an individual, over the entire MAPK cascade 
and consequently on the transcription factor ELK1, which is regulated by this pathway. 
In the putamen of heroin addicts, the protein expression of MEK1 was significantly 
reduced, whereas MEK2 was also lower but not significantly changed. Of the two 
known targets of the MEK1/2, we observe a significant decrease in the protein level of 
ERK1; Conversely, there is a significant increase in the protein levels of ERK2. Dual 
phosphorylations of the ERKs are required for their full activation and for their ability 
to mediate a variety of cellular functions, including activation of downstream 
transcription factors. In the putamen of heroin addicts, the level of phosphorylated 
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ERK1 and phosphorylated ERK2 was not significantly changed when compared with 
control subjects. Elk-1 is directly phosphorylated by ERK1/2, and once activated forms 
a ternary complex on serum response elements (SREs) that activate immediate early 
genes such as c-fos. In the putamen of heroin addicts, the protein expression of Elk-1 
was significantly increased. However, there is a significant reduction in the level of 
phosphorylated Elk-1 in the putamen of heroin addicts. 
The data, about heroin exposure, confirm the presences of perturbations in protein 
levels of the MAPK pathway as a consequence of chronic heroin abuse. 
Moreover, we have shown that the activation of extracellular signal-regulated kinase 1 
and 2 (ERK1/2) resulting in Elk-1 phosphorylation in striatal neurons supporting the 
hypothesis that prolonged exposure to substance abuse causes a dysregulation of MAPK 
pathway, in the areas delegated to the reward. 
Our results could be important to clarify the role of ELK1 in the regulation of several 
gene expression, for changes in neuronal size, in the synaptic connectivity and in 
behavioral plasticity. 
Knowledge of the neuroanatomy, neurophysiology, neurochemistry and 
neuropharmacology of addictive drug action in the brain is currently producing a variety 
of strategies for pharmaco-therapeutic treatment of drug addiction, some of which 
appear promising. 
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1. GENERAL BACKGROUND  
 
 
1.1   Concept and Identification of Addictive Drugs 
 
Defining the set of addictive drugs is complicate in part as it depends on whether 
society considers them to be destructive. For example, evidence for clinical opium 
use extends to 5000 B.C. in Sumeria, where it was known as ‘‘joy plant’’. Arabic 
pharmacologists who wrote on opium, including Galen, mention opium’s clinical use 
and its toxicity but don’t speak about the habit (Tibi, 2006).  
The first scientific article on opium is dated in 1701 by Dr. John Jones, from the 
London College of Physicians (Jones, 1701), who discusses clinical uses, as well as 
withdrawal symptoms, including death, after ‘‘lavish use.’’ Subsequently, studies at 
the Royal Hospital in Greenwich of Dr. John Awsiter have compared opium’s effects 
to those of drunkenness and the outlines features of withdrawal and overdose.  
He further discussed tolerance of large doses by those with opium habit, writing the 
dire consequences for the society (Awsiter, 1763).  
Other researchers, in 1990, had already foreshadowed to be able to treat one habit-
forming drug by prescribing nervous stimulants, which would have included ethanol 
or camphor (Sneader, 1990). It may be that the contemporary concept of addiction 
begins here.  
Over the centuries people have developed different forms of addiction to various 
substances. 
Drug addiction manifests clinically as compulsive drug seeking, drug use, and 
cravings that can persist and recur even after extended periods of abstinence. From a 
psychological and neurological perspective, addiction is a disorder of altered 
cognition.  
The brain regions and processes that underlie addiction overlap extensively with 
those that are involved in essential cognitive functions, including learning, memory, 
attention, reasoning, and impulse control.  
Drugs alter normal brain structure and function in these regions, producing cognitive 
shifts that promote continued drug use through maladaptive learning and hinder the 
acquisition of adaptive behaviors that support abstinence. 
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In a 2005 review, Steven Hyman stated the current neurological conception of drug 
abuse concisely: characterizing addiction as a disease of “pathological learning”. 
This article reviews the knowledges on the cognitive effects of drugs and their 
neurological underpinnings.  
These effects may be particularly disruptive when individuals are exposed to drugs 
during brain development, which lasts from the prenatal period through adolescence, 
and in individuals with mental disorders. 
All addictive drugs have in common that they enhance (directly or indirectly or even 
trans synaptically) dopaminergic reward synaptic function in the nucleus accumbens 
(NA) and for this reason are used self-administration’s drugs  to maintain a high 
level of dopamine (DA) and thus a high level of hedonic. In some classes of 
addictive drugs (e.g. opiates), the tolerance to the euphoric effects develops with 
chronic use.  
The fundamental principle that unites addictive drugs is that each one enhances 
synaptic DA by means that dissociate it from normal behavioral control, so that they 
act to reinforce their own acquisition.  
This occurs via the modulation of synaptic mechanisms that can be involved in 
learning, including enhanced excitation or disinhibition of DA neuron activity, 
blockade of dopamine reuptake, and altering the state of the pre-synaptic terminal to 
enhance evoked over basal transmission.  
Questions about the molecular actions of addictive drugs remain unresolved and this 
explains why the study of addiction treatment  has been challenging. 
 
 
1.2  How the Addictive drugs  acts on the Presynaptic Dopamine 
Neurotransmission  
 
 
 
1.2.1. Identification of a role for Dopamine Neurotransmission in Addiction 
 
The midbrain dopamine neurons, that project to the forebrain, were initially 
identified as a single continuous layer (Dahlstrm	  and	  Fuxe,	  1964), arising from a 
single embryological cell group (Seiger	  and	  Olson,	  1973).  
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However, perhaps because the lateral and medial portions were largely restricted to 
established brain regions the dorsal substantia nigra (SN) and the ventral tegmental 
area (VTA), the lateral and medial portions of this layer were given different labels 
(A9 and A10, respectively) and eventually became identified with two distinct 
nominal systems (a nigrostriatal system and a mesolimbic system (Ungerstedt,	  1971)(Figure 1).	  
These two systems in turn became identified with different functions: the 
nigrostriatal system known to degenerate in Parkinson’s disease, with motor 
function, and the mesolimbic system, important for the habit-forming effects of 
cocaine and for approach behaviors, with motivation and reward function. 
 
 
 
 
 
Fig. 1. Mayor Dopaminergic pathways in the central nervous system 
 
 
 
The nigrostriatal and mesolimbic dopamine ‘‘systems’’ are not simply differentiated 
anatomically, and significant functional interactions between the two systems have 
been widely suggested (Haber	  et	  al.,	  2000). A large body of  evidences shows  that 
the SN dopamine neurons, and not just those of the VTA, play a significant role in 
reward and addiction (Everitt	  and	  Robbins,	  2005). 
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As was noted previously, there is no clear boundary between the two nominal 
midbrain dopamine systems (Figure 2). 
 
 
 
 
 
 
 
Fig. 2. Coronal sections of the ventral midbrain of the rat. The blue line outlines the layer of 
dopaminergic cell bodies and dendrites (dark brown) as revealed by tyrosine hydroxylase 
immunohistochemistry. The green line outlines the GABAergic cell bodies (purple) of the substantia 
nigra pars reticulata (SNr) as revealed by in situ hybridization. The spacing of the cells in the dorsal 
and ventral tiers is evident from in situ hybridization 
 
 
 
Anterograde and retrograde tracing studies show that the SN and VTA dopamine 
cells have overlapping, not distinct, projection fields. The discovery of dopamine 
terminals in prefrontal cortex (PFCx) initially thought to arise uniquely from the 
VTA, prompted postulation of a third (mesocortical) or an expanded 
(mesocorticolimbic) system, but projections to the PFCx were subsequently found to 
arise from the medial SN as well as from the VTA (Fallon	  and	   Loughlin,	   1995). Thus	   it	   is	   no	   longer	   possible	   to	   think	   of	   the	   limbic	   and	   striatal	   dopamine	  systems	  as	  arising	  from	  anatomically	  distinct	  lateral	  SN	  and	  medial	  VTA.	  Thus	   the	  midbrain	  DA	  neurons	  are	   currently	   seen	  as	  a	   final	   common	  path	   for	  the	   rewarding	   effects	   of	   medial	   forebrain	   bundle	   stimulation	   (MFB). The	  mesocorticolimbic	   dopamine	   system	   is	  most	   frequently	   associated	  with	   brain	  stimulation	   reward	   and	   the	   reward	   sites	   are	   found	   in	   both	   SN	   and	   VTA	  (Routtenberg	  and	  Malsbury,	  1969;	  Crow,	  1972).	  In	  this	  region	  are	  activated	  activated	  directly	  the	  sensitive	  terminals	  of	  the	  DA	  afferents	  rather	  than	  the	  relatively	  insensitive	  DA	  neurons.	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1.2.2. Dopamine Action : the Reward  
 
The term “reward”, in the more general meaning, refers to a stimulus or event that is 
rewarding. The  effects of a reward are short-lived and not stored in long-term 
memory, but they can influence the probability and vigor of the next response in a 
series when animals are responding rapidly or when they are responding for slowly 
decaying rewards such as addictive drugs (Gallistel	  et	  al.,	  1974;	  Pickens	  and	  Harris,	  1968).	  
One of the principal neuronal system involved in processing reward information 
appears to be the Dopamine System. The DA projections from the VTA to the NA 
are the key component of the brain reward circuitry. This circuitry provides a 
common way for the valuation of diverse rewards by the brain (Montague	   and	  Berns,	  2002)(Figure 3). 
 
 
 
 
Fig. 3. Main neuronal circuits for mesolimbic dopamine reward system 
 
 
Within the VTA/NA circuit, DA is required for natural stimuli, such as food and 
opportunities for mating, to be rewarding; similarly, DA is required for the addictive 
drugs to produce reward (Kelley and Berridge, 2002; Di Chiara, 1998; Koob and 
Bloom,1988; Wise and Rompre, 1989).  
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The most obvious difference between natural goal objects, such as food, and 
addictive drugs is that the latter have no intrinsic ability to serve a biological need.  
However, because both addictive drugs and natural rewards release DA in the NA 
and other forebrain structures, addictive drugs mimic the effects of natural rewards 
and can thus shape behavior (Montague et al., 2004; Kelley and Berridge, 2002; 
Berke, 2003).  
Indeed, it has been hypothesized that addictive drugs have a competitive advantage 
over most natural stimuli in that they can produce far greater levels of DA release 
and more prolonged stimulation.	  	  
An early view of DA function was that it acted as a hedonic signal (signaling 
pleasure), but this view has been called into question by pharmacological blockade, 
lesion (Berridge and Robinson, 1998), and genetic studies (Cannon and Palmiter, 
2003) in which animals continued to prefer (“like”) rewards such as sucrose despite 
DA depletion.  
Moreover, the actions of nicotine have always remained a mystery on this account, 
because nicotine is highly addictive and causes DA release but produces little if any 
euphoria. Instead of acting as a hedonic signal, DA appears to promote reward-
related learning, binding the hedonic properties of a goal to desire and to action, thus 
shaping subsequent reward-related behavior (Berridge and Robinson, 1998).	  
Berridge and Robinson showed that DA is not required for the pleasurable (hedonic) 
properties of sucrose, which, in their investigation, continued to be “liked” by rats 
depleted of DA.  
Instead they have proposed that NA-DA transmission mediates the assignment of 
“incentive salience” to rewards and reward-related cues, such that these cues can 
subsequently trigger a state of “wanting” for the goal object as distinct from “liking.” 
In their view, an animal can still “like” something in the absence of DA transmission, 
but the animal cannot use this information to motivate the behaviours necessary to 
obtain it. Overall, it can be concluded that DA release is not the internal 
representation of an object’s hedonic properties; the experiments by Schultz (1993) 
suggest instead that DA serves as a prediction-error signal that shapes behavior to 
most efficiently obtain rewards (Schultz et al., 1993). 
This view of DA function is consistent with computational models of reinforcement 
learning (Montague et al., 2004; Sutton and Barto, 1998). Reinforcement learning 
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models are based on the hypothesis that the goal of an organism is to learn to act in 
such a way as to maximize future rewards. 
When such models are applied to the physiological data described earlier, pauses and 
phasic spiking of DA neurons can be conceptualized as the internal representation of 
reward prediction errors by which the planned or actual actions of the monkey 
(“agent”) are “criticized” by reinforcement signals (i.e., rewards that turn out to be 
better, worse, or as predicted).  
DA release can thus shape stimulus-reward learning to improve prediction while it 
also shapes stimulus-action learning, i.e., the behavioral response to reward-related 
stimuli (Schultz et al.,1997).  
Given the likelihood that the addictive drugs exceed natural stimuli in the reliability, 
quantity, and persistence of increased synaptic DA levels, a predicted consequence of 
these hypotheses would be profound over-learning of the motivational significance 
of cues that predict the delivery of drugs. At the same time, much remains unclear. If	  the	  activation	  of	  DA	  neurons	  plays	  a	  significant	  role	  in	  reward	  function,	  these	  neurons	  should	  be	  responsive	  to	  the	  presentation	  of	  rewarding	  stimuli.	  Indeed	  this	  has	  been	  well	  established	  by	  electrophysiological	  studies	  (Schultz,	  1997).  When,	   after	   many	   repeated	   trials,	   an	   animal	   learns	   that	   some	   distal	  environmental	   stimulus	   reliably	   predicts	   the	   presentation	   of	   reward,	   DA	  neurons	  come	  to	  respond	  to	  the	  distal	  predictive	  stimulus	  and	  cease	  responding	  to	   the	   proximal	   reward	   signal	   itself.	   The	   distal	   signal,	   in	   effect,	   becomes	   the	  reward	  signal.	  	  	  	  	  
1.3  How the Addictive drugs acts on the Endogenous Opioid System  
 
Endogenous opioids are small molecules naturally produced in the body that 
resemble morphine and have long been implicated in the actions of opiate drugs and 
alcohol. There are three classes of endogenous opioids: endorphins, enkephalins, and 
dynorphins (Figure 4). 
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Fig. 4. Proopiomelanocortin, preproenkephalin A, preproenkephalin B, and preproorphanin 
FQ (prepronociceptin) precursor molecules and their related cleavage products 
 
 
They all exert their effects by interacting with three subtypes of opioid receptors: µ 
(MOP), δ (DOP), and κ (KOP).  
 
 
1.3.1 Role of Opioid System in Dopamine release  
 
The relations between exogenous opioids and functions of neurotrasmettor and 
neuromodulators are very complex, and act, as is known, through different 
receptor types (Sbrenna et al., 2000, 1999): the exposure of opioid receptors 
to the opiate, produces, as you might expect, tolerance, which is 
selective for the various receptors: the morphine, for example, induce the tolerance at 
the level of MOP, and cross-tolerance compared to other µ-agonists, but this 
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tolerance is selective and does not involve the KOP (Picker et al., 1991).	  The main 
types of opioid receptors are µ, δ and κ (Manallack et al., 1986) (Figure 5) and they 
belong to the family of G protein-coupled receptors have been have been isolated and 
characterized using molecular and pharmacological techniques (Evans et al., 1992; 
Uhl et al., 1994; Knapp et al., 1995). 
 
 
Fig. 5. Mu opioid receptor: located on the membrane of neuronal cells 
 
Endogenous opioid ligands exhibit different preferences for each receptor. β-
Endorphin binds with a higher affinity to µ than δ or k-opioid receptors, naturally 
indicating that it is the endogenous ligand for this opioid receptor type (Khachaturian 
et al., 1993; Simon et al., 1973). The affinity of enkephalins for DOP is 20-fold 
greater than that for MOP receptors, and dynorphin is presumed to be the 
endogenous ligand for KOP (Chavkin et al., 1982; Simon, 1991). Of the other novel 
endogenous opioids isolated, orphanin FQ appears to be an endogenous ligand for 
the nociceptin opioid receptor (NOP) which has a high degree of homology with the 
opioid receptors (Meunier et al., 1995; Reinscheid et al., 1995; Zadina et al., 1997). 
The involvement of opioid receptors in drug dependence has been further examined 
using µ- and δ-opioid receptor knockout mice; µ knockout mice display impaired self 
administration and conditioned place preference for morphine, heroin, alcohol, THC, 
and nicotine (Contet et al., 2004). 
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Recently, reduced locomotor activating effects (Chefer et al., 2004), conditioned 
place preference (CPP) (Hall et al., 2004), and self-administration (Mathon et al., 
2005) of cocaine were shown in MOP knockout mice as well. 
Since different drugs of abuse have different primary loci of action, a prominent and 
general role of the MOP in the rewarding effects of various substances is indicated. 
Several studies show that activation of the opioid system can modulate the secretion 
of DA, which as we have seen is much involved in the reward phenomena. When µ- 
and δ-opioid receptor agonists are self-administered in animal models (Devine and 
Wise, 1994), DA release in the NA increases (Devine et al., 1993). This increase 
occurs via the action of the agonists on GABAergic neurons in the VTA , which 
naturally inhibit DA neurotransmission. 
Indeed some reduction in the levels of DA seems be induced by agonists of the MOP 
(Yonehara and Clouet, 1984) and morphine has shown itself capable of reducing the 
concentration of DA in the portal circulation pituitary action that is reversible under 
the influence opioid antagonist naloxone (Gudelesky and Porter, 1979). 
While the general action of opiates on DA may play a inhibitory character, the other 
the specific stimulatory effect on certain areas of supports the activation of brain 
reward circuit (Sell et al., 1999): in experimental animals seems to be well 
documented that the release of dopamine in the NA represents the biochemical 
substrate capable of determining the additive behavior, both for opiates, and for other 
substances that induce dependence (Herz, 1998; Leshner and Koob, 1999) although 
this mechanism is not yet fully verified in humans (Gratton, 1996), and also a 
significant reduction of DA would occur during withdrawal from opiates (Lichtigfeld 
and Gillman, 1996). 
Ventricular infusions of β-endorphin were shown to increase dopamine release in the 
NA via µ- and δ-opioid receptors (De Vries and Shippenberg, 2002). This increased 
in DA release is likewise due to the inhibitory effect of  β-endorphin on GABA 
blocking DA neurons (Di Chiara and North, 1992).  
Furthermore, β-endorphin-induced reinforcement, as tested by the CPP paradigm, 
correlates positively with an increase in DA release in the NA (Spanagel et al., 
1991).  Interestingly, the reinforcing effect of β-endorphin occurs only at doses that 
stimulate DA release, which suggests that β-endorphin is an endogenous mediator of 
reinforcement, especially for addictive drugs that increase mesolimbic DA 
neurotransmission as a secondary target (Figure 6). 
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Fig. 6. Lengthwise view of the rat brain showing the distribution of endogenous opioid 
 
 
Involvement of  β-endorphin in drug-induced reward and reinforcement is supported 
by several evidence from studies performed during acquisition, maintenance and 
withdrawal stages of addictive drug usage, i.e. cocaine, alcohol, nicotine and THC; 
whether the endorphins are also involved in drug reinstatement has yet to be 
determined. 
The reward pathways for different addictive drugs converge to a common pathway in 
which the β-endorphin is a modulator element. As such, the observed elevations in 
brain levels of β-endorphin during drug self-administration and extinction of the 
drug-reinforced behavior would be functionally significant.  
For example, β-endorphin in the NA may activate appetitive rewarding. This 
possibility is supported by opioid receptor blocker-mediated reduction of the 
conditioned reinforcing effects of addictive drugs. 
Although drugs of abuse have different acute mechanisms of action, their brain 
pathways of reward exhibit common functional effects upon both acute and chronic 
administration (Nestler, 2005), including the involvement of β-endorphin as a 
common mechanism underlying the behavioral effects of substances of abuse was 
reviewed.  
Currently, evidence supports a prominent role for β-endorphin in the reward 
pathways of cocaine and alcohol. 
 12 
 
1.3.2 Addictive behavior mediated by Endogenous Opioid System 
 
 
Animal models for drug dependence, where the characteristic aspects of human drug 
dependence can be mimicked, have provided a useful tool to study the 
neurobiological substrates underlying the dependence-creating properties of drugs of 
abuse. 
Several animal models based on operant conditioned behavior have been used to 
monitor the reinforcing and rewarding effects of addictive drugs. The underlying 
principle of operant conditioning is that consequences control behavior. An animal 
performs since it is reinforced for doing so. Reinforcement can be positive (food, 
water or addictive drugs) or negative (electric shock that can be avoided by making 
the correct response). Animals learn to obtain rewards and avoid punishment by 
responding correctly.  In this context, the role of endogenous opioid system seems to 
be very important. 
Several physiological and behavioral effects of enkephalins and β-endorphin, such as 
rewarding sensations and addictive properties, are similar to those displayed by 
morphine (Belluzzi and Stein, 1977; Goeders et al., 1984; Van Ree et al., 1979). 
Involvement of opioids, such as β-endorphin, in the reinforcing and dependence-
creating properties of drugs has been shown indirectly in pharmacological studies. 
Most of these studies focused on the relation between opioid receptors and drug-
seeking behavior.  
Much evidence exist demonstrating alterations in cocaine-seeking behavior upon 
blockade of µ- and δ-opioid receptors, which are favored by β-endorphin, hence 
indirectly indicating that this endogenous opioid is involved in certain aspects of 
cocaine addiction. 
Low doses of the non-specific opioid antagonists, naloxone and naltrexone, or the 
specific µ-antagonist, CTAP, are sufficient to inhibit cocaine-induced CPP (Gerrits et 
al., 1995; Kim et al., 1997; Kuzmin et al., 1997).  
It may be stated that the vast majority of literature indicates that blockade of opioid 
receptors in the brain decreases both the reinforcing and conditioned motivational 
effects of drug in both animals and humans, depending on a critical dose used (Roth-
Deri et al., 2008). 
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1.4 Addiction as a multistage process 
 
Addiction is defined as compulsive drug use despite negative consequences. The 
goals of the addicted person become narrowed to obtaining, using, and recovering 
from drugs, despite failure in life roles, medical illness, risk of incarceration, and 
other problems. An important characteristic of addiction is its stubborn persistence 
(Hser et al., 2001; McLellan et al., 2000).  
Although some individuals can stop compulsive use of tobacco, alcohol, or illegal 
drugs on their own, for a large number of individuals rendered vulnerable by both 
genetic and non genetic factors (Merikangas et al., 1998; Rhee et al., 2003), 
addiction proves to be a recalcitrant, chronic, and relapsing condition (McLellan et 
al., 2000).  
The central problem in the treatment of addiction is that even after prolonged drug-
free periods, well after the last withdrawal symptom has receded, the risk of relapse, 
often precipitated by drug-associated cues, remains very high (Wikler and Pescor, 
1967; O’Brien et al., 1998).  
A recent reviews characterize addiction as a two-stage process.  
In the first stage, the individual’s occasional drug taking becomes increasingly 
chronic and uncontrolled. 
The neurological source of these symptoms is drug-induced deregulation of the 
brain’s reward system (Feltenstein and See, 2008).  
Normally, increased DA signaling within this system, specifically, in the ventral 
striatum or NA, produces pleasurable feelings. Drugs of abuse hyper-activate this 
system, triggering abrupt and large increases in NA dopamine signaling, producing 
intense sensations that motivate additional drug taking, and promoting the formation 
of maladaptive drug-stimulus associations (Feltenstein and See, 2008). 
Individuals in the second stage of the addictive process present additional clinical 
features, including withdrawal symptoms during early abstinence, persistent 
vulnerability to relapse, and alterations in decision making and other cognitive 
processes. Although modification of the dopaminergic reward system remains 
important at this stage, it probably is not sufficient to maintain these complex and 
long-lasting changes. 
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Kalivas and Volkow (Kalivas and Volkow, 2005) summarize evidence implicating 
drug-induced alterations in signals carried by the neurotransmitter glutamate from 
the brain area that is primarily associated with judgment, the PFCx, to the NA.  
Moal and Koob (Koob and Moal, 2008) emphasize changes in brain stress circuits 
and negative reinforcement (i.e., effects that motivate drug taking by causing 
discomfort during abstinence, such as the onset of withdrawal symptoms).  
Thus, whereas early drug use fosters maladaptive drug stimulus associations that 
contribute to drug seeking and use, later stages disrupt cognitive and other processes 
that are important for successful abstinence. 
 
 
1.4.1 Reinforcement as Consolidation 
 
The term ‘‘reinforcement’’ is unambiguous. It refers only to the seemingly 
retroactive ‘‘stamping-in’’ of recent associations between	   stimuli, stimuli and 
responses, and responses and outcomes that	  occurs when the reinforcer is given after 
the stimulus or response in	  question. Reinforcing actions of a reward depend on this 
temporal	  sequence.  
In its most fundamental sense, reinforcement refers to any treatment that enhances 
the permanence or ‘‘consolidation’’ of a memory trace in the nervous system	  (Landauer,	  1969).	  	  In	  both	  the	  rapid	  time	  frame	  of	  cellular	  models	  of	  synaptic	  potentiation	  and	  the	  more	   prolonged	   time	   frame	   of	   consolidation	   of	   behavioural	   learning	   and	  memory,	  the	  DA	  has	  an	  important	  and	  frequently	  necessary	  role	  and	  at	  each	  of	  these	  levels	  of	  analysis,	  DA	  in	  the	  nigrostriatal	  system	  and	  DA	  in	  the	  mesolimbic	  system	  have	  each	  been	  implicated	  (Figure	  7).	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Fig. 7. Neuronal Pathways Involved With the Reinforcing Effects of different Drugs of Abuse 
 
 
One approach for the study of reinforcement in animal models of alcoholism is a 
procedure called operant conditioning. With this approach, animals are trained to 
perform a response (e.g., press a lever or nose-poke a hole) that results in delivery of 
a stimulus (e.g., a small amount of alcohol) the animals are motivated to obtain. 
Operant conditioning procedures can be fine-tuned to include different work 
requirements for stimuli with varying degrees of motivational value for the 
individual tested. In this procedure models, how in humans, are shown varying 
degrees of willingness to work for alcohol and other drugs under many different 
conditions. 
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1.4.2 Tolerance and Withdrawal  
 
Tolerance in an individual, is the process whereby increasing doses of a substance 
are required over time to give the same effect. It is mediated by a combination of 
post-synaptic receptor down-regulation and reduced receptor sensitivity. 
There may also be changes in pre-synaptic auto-receptors affecting tonic levels of 
DA. In addition there are often compensatory increases in opposing pharmacological 
systems to help maintain a homeostatic balance within brain neural circuits (Taylor 
and Fleming, 2001;  He et al., 2002).  
A consequence of these processes of tolerance is that on abrupt cessation of taking an 
addictive substance, homeostasis is lost and the opponent processes dominate, giving 
rise to withdrawal symptoms. 
The neurotransmitter systems that are affected will vary from substance to substance.  
For instance, with opioids, reduced function of opioid receptors likely occurs through 
altered second messenger systems since few changes in receptor number have been 
found (Nestler, 2001a; 2001b; Nestler and Aghajanian, 1997). 
While increases in phasic DA have a role in mediating initial pleasure, neuro-
adaptations occur in chronic use, resulting in a hypodopaminergic state.  
These changes, occurring in withdrawal and early abstinence, probably underlie 
symptoms such as dysphoria, anhedonia and irritability, and may contribute to 
craving and drug-seeking behavior. 
For some substances, such as stimulants, such symptoms predominate with no or few 
physical symptoms. By contrast, for other substances of abuse such as opioids or 
alcohol, physical withdrawal symptoms can be prominent and contribute 
significantly to their dependency since drug use is to stave off or combat withdrawal. 
This is ‘negative reinforcement’, i.e. taking a drug to overcome an aversive state. 
 
 
1.4.3 Addiction a disease of Learning and Memory 
 
The most distinctive attribute of long-term memory is persistence over time. New 
studies have uncovered many aspects of the molecular and cellular biology of 
synaptic plasticity, and the acquisition and consolidation of memory, which are 
thought to depend on synaptic plasticity. Much less, however, is known about the 
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molecular and cellular biology of long-term memory persistence. Recent findings in 
the field are construed within the conceptual framework that proposes that 
consolidation and persistence of long-term memories require modulation of gene 
expression, which can culminate in synaptic remodeling.(Figure 8).  
 
 
Fig. 8. A Cell Signaling Cascade in Learning and Memory. 
Glutamate binds to α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and N-methyl-d-aspartic acid (NMDA) receptors in the neuron membrane, opening channels for sodium and calcium 
to flow into the cell; calcium influx induces adenylate cyclase to convert adenosine triphosphate 
(ATP) to cyclic adenosine monophosphate (cAMP). cAMP triggers activation, sequentially, of protein 
kinase A (PKA), mitogen-activated protein kinase/extracellular signal-regulated protein kinase 
(MAPK/ERK), and cAMP response element-binding (CREB). CREB attaches to DNA , increasing 
DNA production of protein for the construction of new synapses 
 
The synaptic plasticity is complex, but it can be divided into mechanisms that change 
the strength or “weight” of existing connections and those that might lead to synapse 
formation or elimination and remodeling of the structure of dendrites or axons 
(Chklovskii et al., 2004). The specificity of drug and their relationship to specific 
behavioral sequences suggest that at least some of the mechanisms underlying 
addiction must be associative and synapse specific. 
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The best-characterized candidate mechanisms for changing synaptic strength that are 
both associative and synapse specific are long-term potentiation and long-term 
depression. 
These mechanisms have been hypothesized to play critical roles in many forms of 
experience-dependent plasticity, including various forms of learning and memory 
(Martin et al., 2000; Malenka, 2003). 
 
 
 
1.5 Vulnerability, risk factors and relapse 
 
The brain circuits mediating the pleasurable effects of addictive drugs are 
anatomically, neuro-physiologically and neuro-chemically different from those 
mediating physical dependence, and from those mediating craving and relapse. There 
are important genetic variations in vulnerability to drug addiction, yet environmental 
factors such as stress and social defeat also alter brain-reward mechanisms in such a 
manner as to impart vulnerability to addiction. In short, the 'bio-psycho-social' model 
of etiology holds very well for addiction (Figure 9). 
 
 
 
 
 
Fig.9. Factors determine whether a person will become addicted to drugs 
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Because addiction relapse is a common phenomenon, research in the past decade has 
focused on whether there is a biology underlying relapse susceptibility, and if so, 
whether it is possible to develop new treatments to decrease relapse risk (Sinha, 
2001; Shaham et al., 2003).  
The most common reasons for relapse given by substance-abusing patients include 
stress, negative mood and anxiety, drug-related cues, temptations and boredom, and 
lack of positive environmental contingencies (eg, job, family relationships, 
responsibilities) (McKayn et al., 1995).  
To understand how and why recovering addicted individuals succumb to relapse, 
particularly in the context of external environmental stimuli and interoceptive cues, it 
is important to examine the psychobiological consequences of chronic drug use and 
assess whether such changes are involved in increasing relapse risk. 
High levels of stress and trauma exposure are commonly associated with substance 
use disorders (Sinha, 2008; Enoch, 2011). 
Increases in irritability, anxiety, emotional distress, sleep problems, dysphoria, 
aggressive behaviors, and drug craving are common during early abstinence from 
alcohol, cocaine, opiates, nicotine, and marijuana (Sinha, 2008).  
The dependent state is marked by negative affect, distress, and anhedonia during 
early abstinence, which relates to neuroadaptations in brain reward and stress 
pathways (Sinha, 2001; 2008; Kalivas and Volkow, 2005).  
We can argue that often the same phenomena that can lead to initiation of drug use, 
are often also the cause of relapses. 
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1.6 Ethanol 
 
Ethanol (EtOH) is a psychoactive substance which act with multiple effects on the 
human body, such as: energetic, nutritional, pharmacological, toxic and psychic. 
EtOH , after being ingested, is rapidly metabolized into the stomach by the alcohol 
dehydrogenase enzyme (ADH), and then mostly in the liver by a series of oxidation 
reactions (Figure 10). 
 
 
 
 
Fig. 10. Ethanol structure 
 
 
 
The intermediate metabolite, acetaldehyde, is a reactive and toxic compound, 
contributing to the damage induced by ethanol (Figure 11). 
 
 
Fig.11. Acetaldehyde structure 
 
 
 
EtOH is oxidized to acetaldehyde through the actions of various alcohol ADH 
enzymes (e.g., enzymes encoded by the ADH1B and ADH1C genes), through the 
microsomal enzyme cytochrome P450 2E1 (CYP2E1), and by microbes living in the 
human gastrointestinal tract (e.g., mouth and colon) (Figure 12). 
The relative contributions of these pathways and the differences in activity between 
enzymes encoded by different ADH1B and ADH1C alleles is represented by the 
thickness of the arrows. Acetaldehyde is oxidized to acetate primarily by the enzyme 
aldehyde dehydrogenase 2 (ALDH2). Again, the thickness of the arrows indicates the 
rate of acetaldehyde oxidation in people carrying two active ALDH2*1 alleles, one 
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active ALDH2*1 and one inactive ALDH2*2 allele, or two inactive ALDH2*2 
alleles, respectively.  
The reaction catalyzed by ADH require a consumption of NAD +, whose availability 
is a limiting factor in the metabolism of EtOH, which is why the conversion rate of 
EtOH in the liver is fixed (approximately 8 g or 10 ml per hour for a man of 70 kg). 
The role of CYP2E1 enzyme, which belongs to the cytochrome P450, occurs when 
the amount of EtOH taken exceeds the capacity of the catabolic dehydrogenase. In a 
state of chronic alcoholism, the activity of this enzyme is induced causing an 
alteration in the ability of the liver in detoxification. 
 
 
 
 
 
Fig. 12. Ethanol metabolism 
 
 
 
 
1.6.1 Neurobiology of Alcohol Dependence 
 
Alcoholism is a debilitating disorder for the individual and very costly for society. 
According to the National Institute on Alcohol Abuse and Alcoholism (NIAAA), 
more than 17 million people in the United States either abuse or are dependent on 
alcohol (NIAAA, 2007), with a cost to U.S. society of over $180 billion annually 
(NIAAA, 2004). A major goal of alcohol research is to understand the neural 
underpinnings associated with the transition from alcohol use to alcohol dependence. 
Positive reinforcement is important in the early stages of alcohol use and abuse. 
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Negative reinforcement can be important early in alcohol use by people self-
medicating coexisting affective disorders, but its role likely increases following the 
transition to dependence. Chronic exposure to alcohol induces changes in neural 
circuits that control motivational processes, including arousal, reward, and stress.  
These changes affect systems utilizing the signaling molecules DA, opioid peptides, 
γ-aminobutyric acid, glutamate, and serotonin, as well as systems modulating the 
brain’s stress response. 
These neuro-adaptations produce changes in sensitivity to alcohol’s effects following 
repeated exposure (i.e., sensitization and tolerance) and a withdrawal state following 
discontinuation of alcohol use. Chronic alcohol exposure also results in persistent 
neural deficits, some of which may fully recover following extended periods of 
abstinence. However, the organism remains susceptible to relapse, even after long 
periods of abstinence. Recent research focusing on brain arousal, reward, and stress 
systems is accelerating our understanding of the components of alcohol dependence 
and contributing to the development of new treatment strategies. 
 
 
 
1.6.1.1 Reinforcement and the Transition from Alcohol use to Dependence 
 
Reinforcement is a process in which a response or behavior is strengthened based on 
previous experiences. Positive reinforcement describes a situation in which a 
presumably rewarding stimulus or experience (e.g., alcohol-induced euphoria) 
increases the probability that the individual exhibits a certain response (e.g., alcohol-
seeking behavior) (Gilpin and Koob, 2008). 
Negative reinforcement occurs when the probability of an instrumental response 
(e.g., alcohol-seeking behaviour) increases if this response allows the individual to 
circumvent (i.e., avoidance response) or alleviate (i.e., escape response) an aversive 
stimulus. In alcohol dependence, the aversive stimulus often is composed of 
motivational/affective symptoms (e.g., anxiety, dysphoria, irritability, and emotional 
pain) that manifest in the absence of alcohol (i.e., during withdrawal) and which 
result from prior discontinuation of alcohol consumption. Thus, people may drink to 
prevent or alleviate the anxiety they experience during alcohol withdrawal. In 
conditioned positive and negative reinforcement, stimuli that become associated with 
either alcohol or withdrawal can motivate subsequent alcohol-seeking behavior. 
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Alcohol-drinking behavior is driven by both positive and negative reinforcement, 
although their relative contributions change during the transition from alcohol use to 
abuse to dependence (Gilpin and Koob, 2008). 
 
 
 
1.6.1.2 Positive reinforcement  
 
The positive reinforcing effects of alcohol generally are accepted as important 
motivating factors in alcohol-drinking behavior in the early stages of alcohol use and 
abuse. These effects most often are examined using animal models of self-
administration. With different operant conditioning procedures, researchers can 
determine the time course, pattern, and frequency of responding for alcohol. 
Operant procedures most often are used to examine oral self-administration of 
alcohol, but they also can be used to assess self-administration of alcohol via other 
routes. For example, rats will respond for alcohol infusions directly into the stomach 
(Fidler et al., 2006), blood stream (Grupp, 1981), or brain (Gatto et al., 1994). But 
the reinforcing properties of alcohol can be assessed using different procedures, such 
as the intracranial self-stimulation (ICSS) in specific region hat are important in 
mediating the rewarding properties of alcohol. 
In this procedure, rats are implanted with electrodes in discrete brain regions and 
then are allowed to self-administer mild electrical shocks. if only mild electrical 
stimulation of a certain brain region is required to maintain responding, ICSS is said 
to have a high reward value; if, by contrast, a stronger electrical stimulation of a 
given brain region is required, then ICSS is said to have a lower reward value. 
Alcohol increases the reward value of ICSS because in the presence of alcohol, 
weaker electrical stimulation is required to maintain responding (Lewis and June, 
1990). 
Some recently developed animal models mimic binge drinking in humans. This 
pattern of self-administration, defined in humans as an excessive pattern of alcohol 
drinking that produces blood alcohol levels greater than 0.08 percent within a 2-hour 
period, may be associated with dependence (NIAAA, 2004). Models of binge 
drinking have been developed for both adult (Ji et al.,  2008) and adolescent (Truxell 
et al., 2007) rats and intend to mimic drinking behavior motivated primarily by the 
positive reinforcing effects of alcohol early in the transition to dependence. For 
 24 
example, sweeteners often are added to the alcohol solution in these models, a 
procedure that is thought to reflect the situation in humans because people tend to 
begin drinking alcohol in sweetened beverages (Gilbert, 1978; Samson et al., 1996).  
Other approaches successfully have used genetic selection to produce animals that 
readily self-administer alcohol in a binge-like pattern (Grahame et al., 1999; Lumeng 
et al., 1977). For this approach, can be used models of specific subtypes of 
alcoholism. 
 
 
1.6.1.3 Negative reinforcement  
 
As mentioned above, the early stages of alcohol use and abuse mainly are associated 
with alcohol’s positive reinforcing effects. However, alcohol’s negative reinforcing 
effects may contribute to alcohol-drinking behavior at this stage in people who suffer 
from coexisting psychiatric disorders and use alcohol to self-medicate these 
disorders. 
Comorbidity of alcohol problems (i.e., abuse or dependence) with anxiety and 
depressive/ bipolar disorders is high (44 percent and 50 percent, respectively) 
(Kushner et al., 1990; Weissman et al., 1980).  
Thus, these people may use alcohol to alleviate the symptoms of the coexisting 
disorders. Generally, however, the negative reinforcing effects of alcohol become a 
critical component of the motivation to drink alcohol during the transition to 
dependence, when withdrawal symptoms occur following discontinuation of alcohol 
use and the individual drinks to avoid those withdrawal symptoms. 
In animal models, the negative reinforcing properties of alcohol often are studied 
during periods of imposed abstinence after chronic exposure to high doses of alcohol. 
Such studies have identified an alcohol deprivation effect, that is, a transient increase 
in alcohol-drinking behavior following long-term alcohol access and a period of 
imposed abstinence (Sinclair and Senter, 1967). 
Similarly, chronic inhalation of alcohol vapor can reliably produce large elevations 
in alcohol self-administration (Roberts et al., 1996, 2000a), an effect that is amplified 
when animals repeatedly are withdrawn from the alcohol vapor (O’Dell et al., 2004) 
and which lasts well into protracted abstinence (Gilpin et al., 2008). In general, 
studies using these approaches have demonstrated that the pattern of alcohol 
exposure (i.e., the frequency of withdrawals) appears to be as important as the 
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cumulative alcohol dose in revealing alcohol’s negative reinforcing properties. 
Changes in the reinforcing value of alcohol during the transition from alcohol use 
and abuse to dependence reflect (counter) adaptive neural changes resulting from 
chronic exposure to high alcohol doses. 
As stated above, during the early stages of non-dependent alcohol use, drinking 
behavior largely is motivated by alcohol’s positive reinforcing effects, whereas in the 
dependent state it likely is driven by both the positive and negative reinforcing 
effects of the drug (Figure 13). 
 
 
 
 
 
 
 
 
 
Fig. 13. Changes in the activity of the reward circuit mediating the acute positive reinforcing effects 
of alcohol and the stress circuit mediating negative reinforcement of dependence during the transition 
from nondependent alcohol drinking to dependent drinking. Key elements of the reward circuit are 
DA and opioid peptide neurons that act at both the VTA and the NA and which are activated during 
initial alcohol use and early stages of the progression to dependence (i.e., the binge/intoxication 
stage). Key elements of the stress circuit are corticotrophin-releasing factor (CRF) and norepinephrine 
(NE)-releasing neurons that converge on γ-aminobutyric acid (GABA) interneurons in the central 
nucleus of the AM and which are activated during the development of dependence. 
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1.6.1.4 Brain circuits Mediating Alcohol Reinforcement 
 
Alcohol interacts with several neurotransmitter systems in the brain’s reward and 
stress circuits (Figure 14). 
These interactions produce alcohol’s acute reinforcing effects. Following chronic 
exposure, these interactions result in changes in neuronal function that underlie the 
development of sensitization, tolerance, withdrawal, and dependence. Research using 
pharmacological, cellular, molecular, imaging, genetic, and proteomic techniques 
already has elucidated details of some of these alcohol effects. 
 
 
 
 
 
Fig. 14. Alcohol’s effects on neurotransmitter systems involved in the brain’s reward pathways. 
Alcohol, by promoting γ-aminobutyric acid (GABA) subtype GABAA receptor function, may inhibit 
GABAergic transmission in the VTA, thereby disinhibiting (i.e., activating) VTA dopamine. As a 
result, these neurons release dopamine in the nucleus accumbens, activating reward processes there. 
Similarly, alcohol may inhibit release of the excitatory neurotransmitter glutamate from nerve 
terminals that act on neurons in the NA. Many additional mechanisms (not shown) are proposed, 
through which alcohol may act on these pathways. Some evidence suggests that alcohol may activate 
endogenous opioid pathways and possibly endogenous cannabinoid pathways (not shown). 
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Dopamine Systems. DA is a neurotransmitter primarily involved in a circuit called 
the mesolimbic system. Studies suggest that DA also has a role in the incentive 
motivation associated with acute alcohol intoxication. For example, alcohol 
consumption can be blocked by injecting low doses of a compound that interferes 
with dopamine’s normal activity (i.e., a DA antagonist) directly into the NA (Hodge 
et al., 1997; Rassnick et al., 1993). Furthermore, alcohol ingestion and even the 
anticipation that alcohol will be available produce DA release in the NA as 
determined by increased DA levels in the fluid outside neurons (Weiss et al., 1993). 
However, lesions of the mesolimbic dopamine system do not completely abolish 
alcohol-reinforced behavior, indicating that DA is an important, but not essential, 
component of alcohol reinforcement (Rassnick et al., 1993). Finally, alcohol 
withdrawal produces decreases in DA function in dependent individuals, and this 
decreased DA function may contribute to withdrawal symptoms and alcohol relapse 
(Melis et al., 2005; Volkow et al., 2007) (Table 1). 
 
 
 
 
Opioid Systems. Researchers have hypothesized that positive alcohol reinforcement 
is mediated at least in part by the release of endogenous opioids in the brain. This 
hypothesis is supported by numerous studies demonstrating that opioid antagonists 
acting either at all opioid receptor subtypes or only at specific subtypes suppress 
alcohol drinking in a variety of species and models (Ulm et al., 1995). Moreover, 
complete inactivation (i.e., knockout) of the µ-opioid receptor blocks alcohol self-
administration in mice (Roberts et al., 2000b).  
The agent naltrexone, a subtype-nonspecific opioid receptor antagonist, currently is 
approved as a treatment for alcoholism in humans and is particularly effective in 
reducing heavy drinking. Opioid systems influence alcohol drinking behavior both 
via interaction with the mesolimbic Da system and also independent of the 
mesolimbic DA system, as demonstrated by alcohol-induced increases in 
extracellular endorphin content in the NA (Olive et al., 2001) (Table 1). 
Opioid receptor antagonists interfere with alcohol’s rewarding effects by acting on 
sites in the VTA, NA, and central nucleus of the AM (Koob, 2003). 
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Table 1. Summary of Neurobiological Mechanisms of Alcohol During the Phases of the Addiction 
Cycle Dominated by Positive Reinforcement Versus Negative Reinforcement. 
 
 
γ-Aminobutyric Acid Systems. γ-Aminobutyric acid (GABA) is the major 
inhibitory neurotransmitter in the brain. It acts via two receptor subtypes called 
GABA-A and GABA-B. Alcohol can increase GABA activity in the brain through 
two general mechanisms: 
• It can act on the GABA-releasing (i.e., presynaptic) neuron, resulting in 
increased GABA release; or 
• It can act on the signal-receiving (i.e., postsynaptic) neuron, facilitating the 
activity of the GABA-A receptor. 
Alcohol drinking is suppressed by compounds that interfere with the actions of the 
GABA-A receptor (i.e., GABA-A receptor antagonists) as well as compounds that 
stimulate the GABA-B receptor (i.e., GABA-B agonists) in the NA, ventral 
pallidum, bed nucleus of the stria terminalis, and AM (Koob, 2004). Of these, the 
central nucleus of the AM, a brain region important in the regulation of emotional 
states, is particularly sensitive to suppression of alcohol drinking by compounds that 
act on the GABA systems (i.e., GABAergic compounds) (Hyytia and Koob, 1995). 
Indeed, acute and chronic alcohol exposure produce increases in GABA transmission 
in this brain region (Roberto et al., 2003, 2004) (Table.1). 
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Compounds targeting the glutamate systems also are being used in the treatment of 
alcohol dependence. For example, the agent acamprosate modulates glutamate 
transmission by acting on NMDA and/or metabotropic glutamate receptors 
(Littleton, 2007). Thus, by dampening excessive glutamate activity, acamprosate 
blocks excessive alcohol consumption. Acamprosate’s ability to suppress alcohol 
drinking has been observed across species, and the drug has been approved for the 
treatment of alcoholism in humans, primarily for its perceived ability to reduce 
alcohol craving and negative affect in abstinent alcoholics (Littleton, 2007). 
 
 
 
Serotonin Systems. The neurotransmitter serotonin (also known as 5-
hydroxytryptamine or 5-HT) has long been a target of interest for potential pharmaco 
therapies for alcoholism because of the well-established link between serotonin 
depletion, impulsivity, and alcohol-drinking behavior in rats and humans (Myers and 
Veale, 1968; Virkkunen and Linnoila, 1990) (Table1). 
Pharmacological compounds that target the serotonin system by inhibiting neuronal 
reuptake of serotonin, thereby prolonging its actions, or by blocking specific 
serotonin receptor subtypes have been shown to suppress alcohol-reinforced behavior 
in rats (Johnson, 2008). However, some researchers are debating whether these 
compounds can affect alcohol-reinforced behavior without affecting consummatory 
behavior in general. During alcohol withdrawal, serotonin release in the NA of rats is 
suppressed, and this reduction is partially reversed by self-administration of alcohol 
during withdrawal (Weiss et al., 1996). 
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1.6.2 Epigenetics 
 
 
 
 
1.6.2.1 General consideration 
 
Epigenetics (from the Greek, epi-: επί- over, above; and -genetics) correspond to the 
study of heritable changes in gene expression or in the cellular phenotype caused by 
mechanisms other than changes in the DNA sequence (Feinberg and Tycko, 2004). 
Cellular differentiation is a well know example of relevance of epigenetic 
mechanism. If all cells within an organism have the same DNA (Nestler, 2009) then 
the ability to have different cells with different functions must be due to a selective 
activation or silencing of particular genes within genome (Grewal, 2003). Actually, it 
has been demonstrated that epigenetic events, altogether with genetic events, plays a 
crucial role in tumor progression (Jordà and Peinado, 2010). 
Three epigenetic mechanisms are considered the most important ones: genomic 
imprinting, histone modifications and DNA Methylation (Feinberg and Tycko, 2004) 
(Figure 15). Genomic Imprinting refers to the relative silencing of one parental allele 
compared with the other parental allele as consequence of differentially methylated 
regions within or near imprinted genes. 
Histone modifications, principally acetylation, methylation and phosphorylation, are 
important in transcriptional regulation due the ability to induce chromatin structure 
modification, altering DNA accessibility (Feinberg and Tycko, 2004). DNA 
methylation is the most common epigenetic mechanism (Jordà and Peinado, 2010) 
and consists in a covalent modification of DNA, in which a methyl group is 
transferred from S-adenosylmethionine to the C-5 position of cytosine by a family of 
cytosine (DNA-5)-methyltransferases (Feinberg and Tycko, 2004) and occurs 
predominantly in the cytosines that precede guanines (CpG) (Bird, 1986) (Figure 16). 
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Fig. 15. Pattern of principal components of epigenetic code, DNA Methylation and Histone 
modification. 
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1.6.2.2 Histone modifications 
 
Gene expression can also be modulated by the chromatin state. DNA is packed in the 
nucleus of eukaryotic cells through its chromatin organization. The nucleosome, the 
fundamental unit of chromatin structure, consists of 146 base pairs of DNA 
wrappped around an octamer of histone made up of two copies of each of the core 
histone (H2A, H2B, H3 and H4) (Kouzarides, 2007) (Figure 16). 
 
 
 
Fig. 16. DNA wrapped around histone octamers to form nucleosomes 
 
Each core histone is composed of a structured domain and an unstructured amino-
terminal tail of varying lengths from 16 amino acid residues for H2A, 32 for H2B, 44 
for H3 and 26 for H4, protruding outward from the nucleosome (Taniura et al., 
2007). These proteins provide not only a solid structure; N-terminal regions of 
histones which protrude from the nucleosome are susceptible to interactions with 
other proteins. Chromatin can exist either in a decondensated, active arrangement, 
termed euchromatin, or in a condensated, inactive state, i.e. heterochromatin. 
The post-translational modification of the residues at histone tails are: methylation of 
lysines and arginines, acetylation, phosphorylation, ubiquitination, sumoylation, and 
ADP-ribosylation. Two widely studied histone modifications are histone acetylation 
and phosphorylation. 
Histone acetylation is linked with transcriptional activation, while deacetylation is 
related to transcriptional repression (Berger, 2007).  
Histone acetylation is a reversible modification of lysine residues within the amino-
terminal tail domain of core histone; histone acetyltransferase (HATs) transfers an 
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acetyl-group from acetylcoenzyme A to the ε-amino group of the lysine residue, 
while histone deacetylase (HDACs) acts in the reverse to remove the acetyl group. 
Also histone can be methylated by histone methyltransferases, inducing changes in 
the chromatin structure. 
Methylation may create binding sites for other regulatory proteins thus influencing 
the chromatin structure, either condensating or relaxing the structure (Chouliaras et 
al.,  2010). 
Although DNA methylation and histone modifications can act independently, they 
can also interact with each other. DNA methylation is associated with histone 
modifications through methyl CpG binding proteins interaction with dynamic 
complexes containing histone-modifying enzymes that promote gene repression and 
DNA replication and repair (Klose and Bird, 2006).  
The binding of some deoxy-methylcytosine binding proteins to methylated sequences 
attracts complexes containing co-repressors and histone deacetylases, leading to a 
change in the chromatin structure from an open, trancriptionally active form to a 
more compact, inactive form, inaccessible to the transcription machinery 
(Richardson, 2003). 
 
 
 
1.6.2.3 DNA Methylation 
 
DNA methylation appears to be one of the most important epigenetic mechanisms 
used by the cell, for the establishment and manteinance of the correct patterns of 
gene expression. Indeed, alterations in the patterns of genomic methylation are 
strongly associated with several human diseases, making the use of specific 
inhibitors of the processes involved a common practise in their treatment (Egger et 
al., 2004).  
DNA methylation patterns are stablished during differentiation, and serve to suppress 
genes unnecessary for the function of the mature cell. Demethylation of DNA also 
occurs and involves at least two mechanisms: the first is the mechanism by which 5-
azacytidine (an irreversible DNA Mtase inhibitor) hypomethylates DNA, and a 
second mechanism is that may involve DNA demethylase (Richardson, 2003). 
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DNA methylation in mammals occurs in the cytosin of the CpG dinucleotide via a 
reaction catalysed by enzymes named DNA methyltransferases (DNMTs) and the 
recognition of methylated cytosines is done by proteins that posses a specific binding 
domain, the so-called methyl-CpG binding domain. DNMTs are expressed 
throughout neural development, and in the adult brain in selective regional and cell-
specific patterns including mature stem cell generative zones mediating ongoing 
neurogenesis (Feng et al., 2007).  
Moreover, DNMTs are actively regulated by physiological and pathological states 
and interactions, and they promote neuronal survival, plasticity and stress responses 
(Ooi et al., 2007). In mammals, the DNMT family includes five proteins: DNMT1, 
DNMT2, DNMT3, DNMT3B, and DNMT3L (DNMT3-like). 
On the other hand, the proteins that binds to and recognises 5-methylcytosines are 
the methyl-CpG binding domain proteins in mammals are MeCP2, MBD1, MBD2, 
MBD3 and MBD4. MeCP2 was the first of these proteins to be characterised. 
The methylation of CG sequences can affect nearby gene expression. 
Hypomethylation of regulatory sequences usually correlates with gen expression, 
while methylation results in transcriptional suppressor. In general, the more CpG 
islands located in the promoter of a gene, the more the trancription level is dependent 
on DNA methylation (Graff and Mansuy, 2008).  
Methylation of CpG units disrupts the binding of transcription factors and attracts 
proteins known as methyl-CpG binding domain proteins that are associated with 
gene silencing and chromatin compaction (Antequera and Bird, 1993). 
The CpG islands, regions with more than 500 bp and a G + C content larger than 
55%, are localized in the promoter regions of 40% of all the genes in mammals and 
are normaly maintaind in the non-methylated form (Bird and Wolffe, 1999), but the 
CpGs located outside the CpG islands are usually methylated (Urdinguio et al., 
2009). 
The importance of DNA methylation in the function of normal cells is evidenced by 
its role in differentiation, X chromosome inactivation, genomic imprinting 
maintenance of chromatine structure, and suppression of "parasitic" DNA. 
Methylated citosines can serve as binding platform for specific proteins. On the other 
hand, this modification can also prevent binding of proteins to DNA. 
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It has been observed that multiple exogenous agents can affect DNA methylation, 
and it is possible that transient exposure to a DNA methylation inhibitor can have 
long term effects on DNA methylation.  
 
 
 
1.6.3 Relationship between Alcohol effects and Chromatin Remodeling 
 
Recently, experimental evidences suggest that the variations of gene expression 
induced by drugs of abuse may be mediated by epigenetic mechanisms (Renthal and 
Nestler, 2008). Several studies have demonstrated that intermittent ethanol treatment 
in the rats induces PFCx and hippocampal damage by inflammatory processes, and 
causes important short and long-lasting cognitive and behavioral deficits (Pascual et 
al., 2007). Human epidemiological studies have also demonstrated that early-onset 
alcohol use is associated with an increased risk of subsequent alcohol abuse and the 
development of alcohol disorders, including dependence (Grant and Dawson 1997; 
Hawkins et al., 1997; De Wit et al., 2000). Other studies have also demonstrated that 
the age of first encounter with psychoactive drugs is critical, given the greater 
probability to shift from use to abuse and to develop addiction (Anthony and 
Petronis, 1995; Breslau and Peterson 1996; Patton et al., 2004). Although these 
studies suggest that adolescence is a stage that is vulnerable to the consequences of 
alcohol and other psychoactive drugs abuse, the pathogenic process leading to drug 
addiction is still far from being completely understood. 
The mesolimbic DA system is known to be involved in the reward and reinforced 
effects of drugs of abuse, including alcohol (Koob and Weiss, 1992; Robbins and 
Everitt, 2002). 
Recent evidence suggests that histone modification and chromatin-remodelling 
events are involved in drug-related behavioural sensitization and reward (Schroeder 
et al., 2008), and in particular that alcohol exposure can induce possible mechanism 
for long-term neuro-chemical alterations and recently the chromatin remodeling has 
been reported as a plausible mechanism for alcoholism (Pandey et al., 2008). 
Pandey et al. (2008) have revealed a novel epigenetic mechanism suggesting that, the 
increased histone acetylation and decreased HDAC activity in the AM may be 
involved in the anxiolytic effects of acute EtOH and conversely, decreased histone 
acetylation and increased HDAC activity in the AM may be involved in the 
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development of anxiety during withdrawal after chronic EtOH exposure. The 
cessation of chronic EtOH consumption has been shown to lead to the development 
of withdrawal symptoms both in human alcoholics and animal models (Weiss and 
Rosenberg, 1985; Wilson, 1988; Lal et al., 1993; Pandey et al., 2003). 
These evidence presented here suggests that decreased histone acetylation, 
attributable to increased HDAC activity in the AM during alcohol withdrawal, may 
be associated with withdrawal symptoms, such as anxiety, and that acute EtOH 
exposure may produce anxiolytic effects because of its ability to increase histone 
acetylation through HDAC inhibition (Pandey et al., 2008). 
Moreover,  specific studies conducted in our laboratories have shown that exposure 
to ethanol and its metabolite induce chromatin modifications in neuroblastoma cell 
line on the endogenous opioid system (D’Addario et al., 2011a). 
They have showed a link between gene expression alterations evoked by EtOH and 
acetaldehyde and epigenetic modulation in the promoter region of the PDYN gene, 
proposing a temporal relationship between transcriptional PDYN silencing and 
chromatin alterations. 
The reactivation of the PDYN gene by the same agents on prolonged exposure may 
be related to preferential methylation of H3K4 and acetylation of H3K9 while 
keeping H3K27 un-methylated. This hypothesis is also supported by temporal 
changes in RNA polymerase II (RNAPII) recruitment and activation consistent with 
epigenetic changes. In fact, the increase observed in RNAPII, either total and S5P, at 
72 h after EtOH exposure correlates with the increase at this time point of the two 
activating marks investigated, H3K4me3 and H3K9Ac, but not of the repressive one, 
H3K27me3. In addition, the alteration on H3K9Ac at 48 h becomes more relevant, 
since this histone modification seems to precede not only the reactivation of gene 
expression evident just after 96 h, but also the recruitment and activation of the 
RNAPII (D’Addario et al., 2011a). 
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1.6.4 Pharmacological  Treatment for Alcoholism 
 
The treatment of alcoholism, seeks a full psycho-social rehabilitation of the subject 
and also provides a possible psychosocial intervention, a pharmacotherapy. In this 
case we can identify various stages. A phase of detoxification, preceded, if 
necessary, by treatment of withdrawal syndrome and followed by treatments aimed 
to the relapse prevention. In fact, about half of alcoholics go relapsed after a shorter 
or longer abstaining period (Maisto et al., 2000). 
The main drugs used in the treatment for alcohol-addiction are: disulfiram, 
naltrexone, the acamprosato. Drugs acting on the system  dopaminergic (tiapride, 
amisulpride and flupenthixol), and serotonergic (buspirone, fluoxetine, nefazodone, 
ritanserina and ondansetron) have been and are  currentlysubject of clinical studies. 
Moreover, the mood-stabilizing drugs (Salloum et al., 2005), as well as those acting 
sedative-hypnotic (Kranzler et al., 1994), have demonstrated their effectiveness in 
the presence of psychiatric comorbidity. 
 
 
Disulfiram: The disulfiram causes irreversible inhibition of both, cytosolic and 
mitochondrial, 
the enzyme aldehyde dehydrogenase form (Figure 17). This molecule, by inhibiting 
aldehyde dehydrogenase, causes accumulation of acetaldehyde which is formed by 
oxidation of ethanol by the alcohol dehydrogenase. 
 
 
 
 
Fig. 17 Disulfiram 
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In the presence of disulfiram, alcohol intake is then accompanied the onset of toxic 
effects acetic aldehyde, rather unpleasant and alarming on the subjective level (facial 
flushing, throbbing headache, sweating, nausea, vomiting, tachycardia, dyspnea, 
hypotension, dizziness, collapse). Therefore the goal of treatment with disulfiram is 
to create an aversion alcohol, rather than to modulate the neuropsycho 
pharmacological effects. 
 
 
Naltrexone : Neuropharmacological assumption of the efficacy of opioid antagonists 
is that the endorphins contribute to the effects of positive reinforcement of alcohol 
interacting with the mesolimbic dopamine system, as demonstrated experimentally 
by the fact that the decrease of the self-administration of alcohol is associated with a 
decrease of dopamine release (Gonzales and Weiss, 1998). Indeed, preclinical 
studies, performed in different experimental conditions, agree to observe that the 
administration of µ-receptor antagonists such as naloxone and naltrexone attenuate 
the consumption of alcohol (Herz, 1997; Stromberg et al., 1998) ( Figure 18). 
 
 
 
 
Fig. 18. Naltrexone  
 
 
Clinical studies (Volpicelli et al., 1992; O'Malley et al., 1992) have demonstrated the 
ability of the naltrexone to reduce relapses in heavy drinkers [= heavy drinkers taking 
more than 5 units (1 unit = 10g of alcohol) alcoholic / day], as well as to reduce the 
craving and the frequency of alcohol intake. Unfortunately, not all clinical trials 
subsequently conducted on relapse, have confirmed these positive results. 
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Acamprosate 
The modulatory effects of this molecule on glutamatergic transmission (in 
particular, its action of depression of the transmission and the same 
Activation of NMDA receptors) largely explain its use in therapy 
alcoholism. As known, in fact, one of the bases of the neuropharmacological 
alcohol dependence is established right rising both the number of 
functionality of NMDA receptors (Figure 19). 
 
 
 
 
 
 
Fig. 19. Acamprosate 
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1.7 Heroin 
 
Opiates are among the most commonly abused illegal drugs (Kreek, 1997; Hughes 
and  Rieche, 1995).  
Currently, heroin stands out as the most addictive and destructive illegal drug on the 
planet. It has considerably grave side effects and devastating implications for delicate 
organs of the body like the brain, the CNS and respiratory structure for those who 
take it. Its effects on the brain cause it to lose the capacity to manage normal, 
standard bodily functions thus rendering the body incapable of performing even the 
simplest of tasks.  
 
 
 
1.7.1 Heroin pathways 
 
Heroin is an opioid, regardless of chemical structure, that produces effects similar to 
those of opium and morphine (Wickler, 1980). Heroin has the scientific name 
diacetylmorphine;  its chemical structure is similar to that of 6-acetyl morphine and 
morphine (Figure 20) and is a chronic relapsing disease that is associated with a high 
level of mortality and crime (Hulse et al., 1999). 
The blood brain permeability of heroin is about 10 times that of morphine 
(Washington et al., 2001; Bao et al., 2006). 
 
 
 
 
Fig. 20. Heroin structure after blood brain barrier crossing 
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Once heroin crosses the blood brain barrier, it is hydrolyzed into 6-acetyl morphine 
and morphine, which then quickly bind to opioid receptors (Bao et al., 2006). The 
“rush” felt by heroin users is the sensation caused by the rapid entry of heroin into 
the brain and the attachment of 6-acetyl morphine and morphine to opioid receptors.  
Opioids in general can change the neurochemical activity in the brain stem causing a 
depression in breathing.  In the limbic system opioids cause an increase in feelings of 
pleasure, and have the ability to block pain signals sent through the spinal cord 
(NIDA, 2005) (Figure 21).  
 
 
 
 
Fig. 21. Brain under heroin exposure 
 
 
Several reports suggest that chronic exposure to opiates, such as morphine and 
heroin, can result in cognitive deficits (Guerra et al., 1987; Ciopolli and Galliani, 
1987; Spain and Newsom, 1991). 
For example, heroin users have poorer performance on attention, verbal fluency, and 
memory tasks than controls (Guerra et al., 1987), and rats chronically exposed to 
morphine show impaired acquisition of reference memory (Spain and Newsom, 
1991). Such findings suggest that long-term opiate use may produce maladaptive 
plasticity in brain structures involved in learning and memory. 
The rewarding effects of heroin, like prescription opiate-based drugs, are mediated 
via morphine-dependent activation of the µ-opioid receptor (MOR; Matthes et al., 
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1996; Sora et al., 2001). The opioid receptors, µ, κ and δ, belong to the superfamily 
of G protein-coupled receptors (GPCR). 
Activation of the opioid receptors can modulate multiple effectors, including the 
inhibition of adenylyl cyclise and voltage-gated Ca2+ channels (Gross and 
Macdonald, 1987; Tallent et al., 1994) and the activation of inward rectifying K+ 
channels, phospholipase C (PLC; Spencer et al., 1997) and mitogen-activated protein 
kinase (MAPK) components ERK1 and ERK2 (Fukuda et al., 1996, Cheng et al., 
1996). Activation of the MAPK pathway can occur through the Gαi/o associated Gβγ 
subunits in a Ras-dependent manner as well as by the process of opioid receptor 
phosphorylation by GRK3 and association with β-arrestin2 (Macey et al., 2006). 
Once activated, ERK1/2 can regulate many downstream cytoplasmic and nuclear 
targets to alter gene expression and, as a consequence, events such as synaptic 
plasticity in the brain.  
The physiological output of opioid receptors is dependent primarily on coupling to 
the inhibitory Gαi and Gαo subunits of the heterotrimeric G proteins. However, 
persistent activation of opioid receptors can alter downstream signaling events by 
increasing the responsiveness of Gβγ as well as Gαs subunits.  
In addition, this long-term exposure to opiates also results in receptor desensitization, 
an event which is related to opioid tolerance and dependence. Other compensatory 
measures, such as changes in gene transcription and protein synthesis, which 
contribute to long-term alterations in synaptic function, exist to counter sustained 
activation of the MOR.  
A large meta-analysis recently performed identified a hypothetical common network 
of molecules that underlie addiction to a number of different drugs of abuse (Li et al., 
2007). 
Genetic components contribute significantly to susceptibility to heroin addiction (40-
60%) and gene variants such as those encoding opioid receptors have been shown to 
be associated with this disease. The most widely-studied single nucleotide 
polymorphism (SNPs) in the OPRM1 gene are located within exon 1 (A118G and 
C17T variants) and encode amino acid substitutions in the extracellular N terminus 
of the receptor.  
In particular, the A118G variant has been associated with an enhanced response to 
therapies for alcohol and nicotine dependence and positive susceptibility to opioid 
addiction (Kroslak et al., 2007). 
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In contrast, other studies, including two meta-analyses of case-controlled subjects, 
failed to detect an association of the A118G variant with opioid dependence. These 
inconsistencies are likely a reflection of the high linkage disequilibrium the A118G 
SNP has with other causative variants.  
There are also conflicting reports in the literature that describe the impact the amino 
acid substitution (N40D) has on receptor binding in in vitro studies. However, the 
118G variant is associated with reduced OPRM1 mRNA levels in human brains and 
in decreased receptor levels in cells expressing the same variant (Kroslak et al., 
2007). Furthermore, a mouse model possessing the equivalent SNP in the OPRM1 
gene (A112G) also showed reduced mRNA expression and receptor protein levels, as 
well as reduced morphine-mediated hyperactivity and anti nociception (Mague et al., 
2009). 
Over 100 SNPs have been identified in the OPRM1 gene and a number of these 
variants have been associated with a varied response to alcohol (Ehlers et al., 2008), 
intiation of smoking (Zhang et al., 2006a) and the initial positive response to heroin 
(Zhang et al., 2006b). 
The signaling and transcriptional reprogramming that underlies adaptations of the 
brain to chronic heroin exposure is currently poorly understood. 
When heroin is injected or smoked, users typically feel two types of euphoric effects, 
a “rush” and a “high.”   
The rush usually lasts one to two minutes and occurs right after the drug is 
administered.  It is described as an intense feeling that is felt throughout the body, 
especially in the abdomen.   
Following the rush is a high that can last four to six hours.  The feeling is described 
as  pleasant, with indifference to internal and external stimuli.  The following 
characterizations may occur during a high (Stimmel, 1992). Timing of Effects : 
injecting heroin intravenously can produce a feeling of euphoria in seven to eight 
seconds. The peak effects of smoking heroin are similar to those obtained from 
intravenous injection (Cone, 1998). In contrast, injecting intramuscularly,  leads to a 
slower onset of euphoria, taking five to eight minutes (NIDA, 2005).  
The peak effects of snorting heroin occur in 10 to 15 minutes (NIDA, 2005) whereas 
the oral administration has little effect.   
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1.7.2 Priming, Addiction and Withdrawal 
 
A large body of evidence indicates that the reinforcing effects of heroin  are 
mediated by the drugs actions in the VTA, (the cell body region of the mesolimbic 
dopamine system) and in the NA (a terminal region of this system) (Wise, 1996). 
Results from studies using systemic drug injections indicate that dopamine 
neurotransmission mediates cocaine-induced reinstatement (Self and Nestler, 1998; 
Shalev et al., 2002; Spealman et al., 1999). Reinstatement induced by cocaine and 
heroin priming is mediated by activation of dopamine D2-like, but not dopamine D1-
like, receptors (Alleweireldt et al., 2003; De Vries et al., 1999; Khroyan et al., 2000; 
Marinelli et al., 2003; Self et al., 1996; Wise et al., 1990). 
In earlier studies, Stewart (1984) found that intra-VTA infusions of morphine, which 
increases dopamine cell firing and release, reinstate heroin or cocaine seeking, and 
intra-accumbens infusions of amphetamine, which increases local DA release, 
reinstate heroin seeking. Based on these studies and studies using systemic drug 
injections, there was, until recently, a consensus that accumbens DA activity 
mediates reinstatement induced by heroin priming. In another study, Luo et al. 
(2004) trained rats to self-administer heroin or saline (a control condition) and after 
extinction of the drug-reinforced responding they examined in different groups the 
effect of heroin priming injections on reinstatement or fMRI signal in several brain 
areas, including components of the mesocorticolimbic system. The main finding was 
that rats with a history of heroin self-administration showed profound tolerance to 
the effect of heroin priming on the Functional magnetic resonance imaging (fMRI) 
signal. The significance of these findings, however, is not clear because previous 
studies have shown that the effects of heroin and dopaminergic drugs on 
reinstatement of heroin seeking is highly correlated with their ability to induce 
locomotor sensitization (De Vries et al., 1998; De Vries and Shippenberg, 2002). 
 
 
1.7.3  Heroin Relapse 
 
The central problem for treatment of heroin addiction remains the return to drug use 
after periods of abstinence (relapse) (Mendelson and Mello, 1996; O'Brien, 1997; 
Wallace, 1989). Studies in humans provide evidence that relapse to heroin or cocaine 
use or craving for these drugs can be triggered by exposure to the self-administered 
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drug (De Wit, 1996; Meyer and Mirin, 1979), drug-associated cues (Carter and 
Tiffany, 1999; Childress et al., 1993) or stress (Sinha, 2001). 
Others have argued that this clinical scenario can be modelled in a reinstatement 
model using laboratory rats and monkeys (Epstein and Preston, 2003; Shaham et al., 
2003; Spealman et al., 1999; Stewart, 2000). 
In the operant version of the reinstatement model, laboratory animals are trained to 
self-administer drugs and are then subjected to extinction training during which lever 
presses are not reinforced with drugs.  
Reinstatement of extinguished lever responding (the operational measure of drug 
seeking) is determined after such manipulations as non contingent priming injections 
of the drug (deWit and Stewart, 1981; Stretch et al., 1971), exposure to cues 
associated with drug intake (Davis and Smith, 1976; Meil and See, 1996) or 
exposure to stress (Erb et al., 1996; Shaham and Stewart, 1995). 
During testing for reinstatement, extinction conditions remain in effect (drug is not 
available). In the conditioned place preference (CPP) variation of the reinstatement 
model, laboratory animals are trained to associate a distinct environment with drug 
injections and are then subjected to extinction training during which they are exposed 
to the same environment in the absence of drug.  
Resumption of preference for that environment is then determined after non-
contingent priming injections of the drug (Mueller and Stewart, 2000; Parker and 
McDonald, 2000) or exposure to stress (Sanchez and Sorg, 2001).  
The effects of drug-associated cues on relapse to drug seeking can also be examined 
in extinction tests that are administered at different days after the termination of drug 
self administration (Di Ciano and Everitt, 2004; Lu et al., 2004; Tran-Nguyen et al., 
1998). This permits characterization of the time course of susceptibility to relapse to 
drug seeking.  
 
 
1.7.4 The MAP Kinase  Pathway 
 
The MAP kinases (MAPK) are phosphorylated enzyme activities that regulate 
various biological mechanisms such as gene expression, metabolism, proliferation 
and programmed cell death and cell motility. These enzymes, once activated, they act 
on different target proteins that other proteins may be kinases, transcription factors, 
phospholipases, and cytoskeletal proteins and determining the level of 
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phosphorylation at specific serine and threonine residues with activation or inhibition 
of their activities (Figure 22). 
 
 
 
 
 
Fig. 22. The Mitogen-Activated Protein Kinase Pathway 
 
 
 
 
Molecular Machanisms The activation of various MAPK provides a sequence of 
phosphorylations by different kinases activated in succession. Starting from an 
extracellular stimulus is coming, following the activation cascade of different 
substrates, the MAPK phosphorylation of the final will go to that then phosphorylate 
target proteins localized in different cellular regions (Chang and Karin, 2001).   
In particular, the cascade of activation generally begins at the hands of a small G 
protein (Ras) that transmits a signal activating a MAPKKK that phosphorylates, at 
specific serine residues and \ or threonine, a MAPKK which, in turn, phosphorylates 
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and active, through a dual tyrosine and threonine phosphorylation, the MAPK itself 
(Yoav et al., 2006).  
In particular, an example of activation mechanism involving tyrosine kinase 
receptors for growth factors.  
The cascade begins with activation of receptor tyrosine phosphorylation in response 
to the link with growth factors. The tyrosine phosphorylated binds directly or through 
the adapter Shc, Grb2 protein, responsible for the recruitment of Sos and subsequent 
activation of Ras, which, through Raf and MEK kinase, phosphorylates the MAPK 
(including ERK) that are thus activated. Another activation mechanism is the 
involvement of G protein-coupled receptors (G protein coupled receptors, GPCRs). 
In the case of Gq protein-coupled receptors, diacylglycerol (DG) of phosphoinositide 
hydrolysis, which forms the membrane, activates protein kinase C (PKC) that 
phosphorylates Raf, MEK and therefore responsible for the activation of ERK. The 
MAPK phosphorylation site recognized by the always consists of a tyrosine or a 
threonine followed by proline. The phosphate groups that both the MAPK substrate 
proteins are then removed by specific phosphatase resulting signal is switched off 
(Yoav et al., 2006). 
 
 
 
1.7.4.1 ERK  1 / 2   
 
The ERK 1 \ 2 are widely expressed and are involved in the regulation of 
proliferation and cell differentiation and neuronal plasticity. ERK proteins are 
products of two genes, ERK 1 (Mapk3) and ERK2 (Mapk1) (Boulton et al., 1991). 
Besides the two major proteins ERK1 (44 kDa) and ERK 2 (42 kDa) protein 
isoforms are known to other members of the same family including ERK1b (46 kDa) 
typical of rodents (Yung et al., 2000) and ERK2c ERK1b and their primate 
(Aebersold et al., 2004; Gonzalez et al., 1992). The involvement of ERK 1 / 2 in 
long-term memory (long-term memory, LTM) has been demonstrated by various 
behavioral and biochemical studies. 
With the test of Morris has been shown that, following administration of inhibitors of 
ERK, treated animals took a much longer time to perform the test compared to 
control animals.  
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When learning was also observed an increased activity of hippocampal ERK. In 
neuronal cells, neurotransmitters such as DA and norepinephrine, through their 
receptors coupled to adenylate cyclase, or acetylcholine through muscarinic receptors 
coupled M1 type of phosphoinositide hydrolysis, can stimulate the' activities of 
ERK, and then , influence the neuronal plasticity.  
The ERKs are also able to facilitate gene transcription by modifying chromatin 
structure through the activation of kinases that determine the relaxation of the DNA 
double helix by increasing the access of transcription initiation factors.  
Once activated by various extracellular stimuli or internal processes of the ERK 
pathway are involved in the processes of proliferation, cell differentiation, regulating 
the expression of genes necessary for cell growth and division, and the effect of the 
enzyme-dependent translocation to the nucleus, determine the increase in the 
synthesis of nucleotides necessary for the formation of new molecules of DNA and 
RNA and cellular proteins. 
All ERKs are activated by a double phosphorylation at residue tyrosine and threonine 
regulators. This dual phosphorylation appears to be mediated by MEK. 
Following mutational analysis has discovered a region in the C-terminal portion of 
the ERK (amino acids 312 to 320 of ERK2) important for interaction with MEK 
(Rubinfeld et al., 1999; Chuderland and Seger, 2005). 
The most important residues for interaction in this region are 3 amino acids (Asp316, 
Asp819, Glu320 in ERK2). This region is able to interact with three and two basic 
residues located in the hydrophobic N-terminal portion of MEK called domain D 
(Zhou et al., 2006). 
Crystallization studies have shown that the binding of the domain D with the ERK 
pathway induces a conformational change that exposes the threonine and tyrosine 
residues outside regulators allowing the attack of MEK and phosphorylation of these 
residues (Pulido et al., 1998). 
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1.7.4  ETS family and ELK1  
 
The ETS-domain transcription factor Elk-1 was first discovered in a fraction of HeLa 
cell nuclear extract that formed ternary complexes with the serum response factor 
(SRF) on the c-fos serum response element (SRE)(Shaw et al., 1989). This protein 
was thus named p62TCF, based on its properties of being a 62 kDa protein and being 
a ternary complex factor (TCF). 
The TCFs represent a subfamily of the ETS domain transcription factor family 
(Graves and Petersen, 1998; Sharrocks, 2001). These transcription factors are 
characterized by the presence of the ETS DNA-binding domain, and sequence 
conservation within this domain alone is sufficient to classify ETS-domain proteins 
into subfamilies. Elk-1 is the best studied of the TCFs, and several functional 
domains/motifs have been identified (Figure 23). 
 
 
 
  
 
Fig. 23. Domain structure of Elk-1 
The locations of the ETS domain, B-box (SRF interaction) motif, Rmotif, D-domain, FxF 
motif [MAP kinase (MAPK) binding] and TAD are indicated. The ETS domain and the R-
motif exhibit transcriptional repression activity. The TAD also overlaps the regulatory region 
of the protein that is phosphorylated (P) by MAP kinases. 
 
 
Elk-1 was initially identified as part of a ternary complex with SRF on the c-fos SRE. 
Since then, the molecular and structural details of how this complex is assembled and 
regulated have been elucidated. It is recruited to the SRE by a combination of 
protein-DNA and protein-protein interactions (Figure 24).  
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Fig. 24. Structure of the TCF–SRF–SRE ternary complex 
 
 
The formation of the ternary complex can be regulated at several levels. For 
example, phosphorylation stimulates ternary complex formation by Elk-1 (Janknecht 
et al., 1994; Gille et al., 1992). 
Binding of Elk-1 to the c-fos SRE in the absence of SRF cannot be detected, 
suggesting that protein-protein interactions with SRF are a pre-requisite for its 
recruitment (Hipskind et al., 1991). But at the same time, this stimulation can also be 
observed with high-affinity ETS binding sites in the absence of SRF (Sharrocks, 
1995), indicating that this enhancement is mediated, at least in part, by promotion of 
protein/DNA interactions via the ETS domain. Conversely, ternary complex 
formation and autonomous DNA binding by Elk-1 and other TCFs can be inhibited 
by interaction with members of the Id subfamily of helix-loop-helix proteins. 
The TCFs are direct targets of the MAP kinases, and Elk-1 was the first TCF shown 
to be regulated by ERKs (Hill et al., 1993; Marais et al., 1993). 
 
Phosphorylation of Elk-1 both enhances its recruitment to DNA (either in ternary 
complexes or autonomously) and potentiates its transcriptional activation activity. 
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ERK-mediated Elk-1 phosphorylation is also thought to promote the formation of 
quaternary complexes containing two Elk-1 molecules (Gille et al., 1996). 
Recently, the mechanism by which MAP kinases recognize and interact with the 
TCFs has been elucidated in detail. While the local context of the phosphoacceptor 
motifs plays an important role in specificity determination for a particular type of 
MAP kinase, docking modules also play a major role in specificity determination. 
In Elk-1, the D-domain and FxF motif constitute a bipartite docking module that 
dictates its selective phosphorylation by ERK and JNK MAP kinases, but selects 
against phosphorylation by p38 (Yang et al., 1998; Jacobs et al., 1999). 
In Elk-1 the FxF motif is responsible for directing the preferential phosphorylation of 
the critical Ser-383 residue (Fantz et al., 2001). 
However, while it should be emphasized that Ser-383 is clearly the most important 
residue for Elk-1 function, Elk-1 contains multiple MAP kinase sites that are 
phosphorylated to a high stoichiometry in vivo (Cruzalegui et al., 1999). The 
function(s) regulated by the other MAP kinase sites in Elk-1 are currently unknown. 
Phosphorylation of the TCFs regulates a number of key activities. A sequential series 
of events is triggered by phosphorylation by MAP kinase of the C-terminal 
regulatory domain of Elk-1 (Figure 25). 
 
 
 
 
Fig. 25. Role of phosphorylation in Elk-1 regulation 
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4. AIM OF RESEARCH 
 
The research project conducted during these years, is focused on the effects evoked 
by drugs of abuse in the central nervous system (SNC). 
Within this context, our attention has focused on the study of phenomena associated 
with the consumption of alcohol and heroin. 
Alcohol is the drug of abuse certainly more socially accepted and alcoholism, a 
condition that occurs following chronic use of alcohol is the cause of many deaths, 
just think that in Italy every year there are approximately 50,000 new alcoholics and 
40,000 deaths related to alcohol. Recent data from the Italian Institute of Health 
indicate that about 1 and a half million young people (aged between 11 and 24 years) 
are at high risk of alcoholism.  
Although alcohol has long been considered an unspecific pharmacological agent, 
recent studies of molecular pharmacology have shown that acts on different primary 
targets, including ion channels and receptors, kicking off a cascade of synaptic 
events involving many neurotransmitter systems. However, it should be noted that 
prolonged use at high doses induces alterations on all systems and thus becomes 
difficult to define which of these is the most involved. 
Despite considerable progress in explaining the contribution of the susceptibility 
factors to the development of alcohol dependence, the exact mechanism of this 
phenomenon remains unclear. In particular there are two big questions to be 
answered: 
• what are the genetic and environmental factors that cause the initiation and 
maintenance of alcohol consumption  
• what are the changes in the brain behind the transition from control to a 
compulsive use 
Genetically, we can determine non-specific susceptibility factors that increase the 
risk of developing alcohol dependence, including contemporary psychiatric disorders 
and depressive disorders more serious, while on a personal level or passive 
dependence and antisocial impulsive behavior may lead to different individual 
responses (Cloninger, 1987).  
These factors have been proposed to reflect the hypothesis of differences in 
neurotransmitter systems of the brain, which in turn can influence the 
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pharmacodynamics of alcohol, and also determine, minimally, an individual 
variability in search of substance. 
A large number of studies suggest that the endogenous opioid system appears to be 
an important target for the mediation of the mechanisms associated with alcohol 
consumption (Koob et al., 1998).  
Through studies conducted in recent years on gene expression, it has been shown that 
the classical opioid receptors are differently involved in the consumption of ethanol 
(Roberts et al., 2001) and, furthermore, the system nociceptin / NOP, recently 
included in the family of endogenous opioid system, and both appear able to play a 
key role in the initiation of alcohol use in rodents (Ciccocioppo et al., 2004). 
In particular, naltrexone, known opioid antagonist, if taken daily in alcohol abusers, 
following a period of detoxification, can reduce the frequency of relapse in some 
groups of patients (Volpicelli et al., 1992) because it is able to revert the increased 
release Dopamine in the NA (Gonzales and Weiss, 1998). 
Several studies have also shown that nociceptin exhibits high structural similarity 
with the DYN and can interact with a G protein coupled receptor, NOP, whose 
sequence is very similar to that of the KOP. Despite the high degree of similarity 
between these two systems, they appear to exert opposing physiological functions, in 
particular, there is a real functional antagonism of the nociceptin system against the 
endogenous opioid system (Reinscheid et al., 1998).  
Genetic studies have shown the presence of polymorphisms in genes coding for KOP 
and for the precursor of its ligand, the PDYN, which is associated with the risk of 
developing alcohol dependence (Xuei et al., 2006). 
It was also observed that variations in genes coding for the nociceptin system, for 
NOP receptor and for the precursor of its ligand, the pronociceptin/Orphanin FQ 
(PNOC), are associated with alcoholism (Xuei et al., 2008). 
What emerges is that manipulation of the opioid system, nociceptin in particular, 
may be useful in the treatment of addictions and there are several evidences that 
support the use of this strategy (Sakoori and Murphy, 2004; Kotlinska et al., 2003). 
Based on these findings, the primary aim was to evaluate the effects on gene 
expression induced by ethanol precursors of opioid peptides (PNOC and PDYN) and 
their respective receptors in different regions of the brain associated with addiction 
and to understand the physiological function of N / OFQ in endogenous reward and 
the development of addiction.  
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Our interest has focused in particular on the analysis of the PFCx where there is a 
high density of opioid receptors (Mansour et al., 1987). 
The PFCx (Fuster, 2001; Miller and Cohen, 2001) is a region of considerable interest 
in opiate addiction because it plays an important role in cognitive control over drug 
intake (Moghaddam and Homayoun, 2008), and also because it is directly related 
with the meso-corticolimbic dopaminergic system that mediates the rewarding and 
addictive properties of opiates (Volkow et al., 2003; Everitt et al., 2007; 
Schoenbaum and Shaham, 2008). The PFCx is involved in the processes of response 
to sensory stimuli (Devinsky et al., 1995) and alcoholism is also often accompanied 
by signs of dysfunction in charge of PFCx (Lyvers, 2000). 
Based on these results we have continued studies of gene expression to evaluate if 
the same experimental conditions could lead other modifications in the AM area, an 
important substrate for neuronal behavior associated with the consumption of alcohol 
and anxiety (Fadda and Rossetti, 1998; McBride, 2002).  
In fact, anxiety is one of the first symptoms linked to the  abstinence and it’s also an 
important factor in negative reinforcement, which leads to excessive consumption of 
alcohol  (Weiss et al., 2001; Pandey, 2003). 
Recently, an increasing number of experimental evidence suggest that changes in 
gene expression induced by drugs of abuse may be mediated by epigenetic 
mechanisms (Renthal and Nestler, 2008). There are two types of chromatin 
modifications involved in the regulation of gene transcription: histone modifications 
and DNA methylation.  
Other mechanisms such as RNA interference and prion proteins may contribute to 
epigenetic regulation. Chromatin is the form in which nucleic acids are organized in 
the nucleus of the eukaryotic cell and is composed of DNA, RNA and proteins. It has 
a particularly dynamic structure, responds to extracellular signals and controls gene 
expression (Kouzarides, 2007; Bernstein et al., 2005). 
The histone modifications are posttranslational events and occur on the N-and C- 
tails which protruding from the surface of the chromatin polymer. They include 
acetylation, phosphorylation, methylation and ADP-ribosylation. 
These changes end up altering chromatin structure by influencing histone-DNA and 
histone-histone contacts. 
In contrast to the transient nature of phosphorylation and acetylation, methylation of 
histones seems to be a relatively stable signature for the long-term maintenance of 
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the state of chromatin (Schubeler and Elgin, 2005).  Increasing evidences on the 
relationships between changes in methylation of lysine on histone 3, and alteration of 
gene expression are evident (Boggs et al., 2002). 
Epigenetic mechanisms seem to play a role in the cellular effects induced by EtOH 
(Shukla and Aroor, 2006) and, recently, the chromatin remodeling has been reported 
as a plausible mechanism for alcoholism (Pandey et al., 2008). 
With this purpose, studies have been performed using epigenetic Chromatin Immuno 
Precipitation assays (ChIP) in order to observe different changes in the promoter 
regions of several target genes, related to the alterations in gene expression, evoked 
by alcohol exposure. 
Moreover, many findings suggest that hypo-methylation of the DNA surrounding the 
promoter region is a prerequisite for gene activation, and that a high methylation 
status may mead to the loss of transcriptional activity (Hsieh, 1994; Furuta et al., 
2008). 
In the second part of the present study, I also investigated alterations in signaling 
molecules directly associated with MAPK pathway in a unique collection of post-
mortem brains from heroin abusers.  
The reinforcing effects of opiate drugs, like heroin, are mediated by opiate receptors 
in the VTA (Bozarth and Wise, 1981), NA (Olds, 1982), and hippocampus (Stevens 
et al., 1991) through both DA-dependent and, independent mechanisms. Following 
chronic heroin self-administration, neuro-adaptations in mesolimbic DA neurons and 
their target regions are thought to play a central role in the maintenance of opiate 
addiction (Koob and Le Moal, 2001; Nestler and Aghajanian, 1997; Self and Nestler, 
1995). 
In this context, chronic morphine exposure in rats resulted in structural changes of 
neurons compatible with the induction of synaptic plasticity (Sklair-Tavron et al., 
1996; Robinson and Kolb, 1999; Spiga et al., 2003; Liao et al., 2005; Ballesteros-
Yáñez et al., 2007). 
Although some signaling pathways have been associated with morphine-induced 
changes in neuronal size, synaptic connectivity and behavioral plasticity, increasing 
evidences indicate that proteins of the apoptotic pathways can also play relevant 
roles in promoting various forms of synaptic plasticity (Gilman and Mattson, 2002; 
Mattson and Gleichmann, 2005; Mattson, 2007). 
 56 
Given that opiate receptors are coupled to inhibitory G proteins that reduce cyclic 
AMP formation (Childers, 1991), a compensatory up-regulation in cyclic AMP-
dependent protein kinase (PKA) has been reported in the NA following chronic 
heroin self-administration (Self et al., 1995). Increased PKA activity in the NA 
causes elevated drug and alcohol intake (Self et al., 1998; Wand et al., 2001) and 
exacerbates the aversive aspects of opiate withdrawal. 
Several studies have implicated ERK1/2 and p38 MAPKs in the modulation of 
various forms of synaptic plasticity (Derkinderen et al., 1999; Thomas and Huganir, 
2004), including the neuroplastic changes induced by drugs of abuse (Girault et al., 
2007). 
In addition to PKA-mediated protein phosphorylation, extracellular signal-regulated 
kinase (ERK) activity may also be regulated after heroin exposure. All ERKs are 
activated by a double phosphorylation at residue tyrosine and threonine regulators 
and among their molecular targets we find ELK1, the best members studied of the 
TCFs. We already know that TCFs are direct targets of the MAP kinases, and Elk-1 
was the first TCF shown to be regulated by ERKs (Hill et al., 1993; Marais et al., 
1993). Previous studies have shown that amphetamine activates extracellular signal-
regulated kinase 1 and 2 (ERK1/2) resulting in cAMP response element-binding 
protein (CREB) and Elk-1 phosphorylation in striatal neurons (Choe and Wang, 
2002).  
On basis of these findings, my interest is focused on understanding the effects that 
prolonged exposure of heroin can cause in an individual, over the entire MAPK 
cascade and consequently on the transcription factor ELK1, which is regulated by 
this pathway. 
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3. MATERIALS AND METHODS 
 
3.1 Ethanol studies in animals model  
 
3.1.1 Animals and Treatments 
 
All animal experiments were carried out in accordance with the European 
Communities Council Directive of 24 November 1986 (86/609/EEC) and National 
(Ministry of Health) laws and policies (authorization no. 204/2008-B). Carewas 
taken to minimize the number of experimental animals and to take measures to 
minimize their suffering. 
Adult male SpragueDawley rats (Harlan, Udine, Italy) weighing 330–360 g at the 
beginning of the experiment were housed two per cage in standard Macrolon cages 
(Tecniplast Gazzada, Buguggiade, Italy) in a temperature- and humidity-controlled 
room with a constant 12-hour light/dark cycle (lights on at 7am).The rats were 
allowed to acclimatize for at least 1 week before the start of the experiments. 
Free access to standard lab chow and tap water were available ad libitum. Alcohol or 
water was administered intragastrically by oral gavage (Figure 26) by using a slightly 
bent stainless steel feeding needle. No restraint was used. The procedure was 
finished within 10 seconds. 
 
 
 
 
Fig. 26. Procedure for Oral Gavage 
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Preliminary results from our laboratory showed that a single intragastric 
administration of 20% EtOH at a dose of 3 g/kg induced a long lasting loss of 
righting reflex (LORR) and eventually coma.  
This dose induced an up-regulation of PDYN and PNOC gene expression in the AM 
dissected 30 minutes after the treatment; whereas no changes were observed after 2 
hours, the other timepoint investigated. Moreover, a low dose of EtOH (0.75 g/kg) at 
both the timepoints (30 minutes and 2 hours) did not induce any changes in opioid 
genes expression (data not shown). 
On the basis of these results and previous report (Zhou et al., 2000), a binge alcohol 
paradigm was chosen to more closely resemble human drinking behavior with 
several hours of heavy alcohol exposure by the oral route. 
Hence, animals received daily intragastric administrations of alcohol (20% in water) 
at a dose of 1.5 g/kg or equal volume of water in their home cages following this 
binge pattern regimen: three times daily at 1.5-hour intervals (10:00 am, 11:30 am, 
and 1:00 pm), for a total daily dose of 4.5 g/kg/day. 
Two groups of rats received EtOH (1D group; n = 7) or water (control group; n = 7) 
for 1 day, were killed by decapitation and brain regions of interest were rapidly 
dissected and frozen on dry ice 30 minutes after the treatment. This timepoint was 
chosen based on preliminary studies as mentioned above. 
EtOH or water (control) were also administered to other groups of animals (n = 7 for 
each group: three groups administered with EtOH and three groups with water) for 5 
days and, depending on the end-point and based on the behavioral studies described 
below, they were named as 5D (rats killed 30 minutes after the last EtOH or water 
administration), 1 day withdrawal (W-1D), 3 days withdrawal (W-3D) or 7 days 
withdrawal (W-7D) (rats killed 1, 3 or 7 days after the last dose of EtOH or water), in 
accordance with the behavioural parameters assessed (see Table 2 for synopsis of the 
experimental design).  
 
 
Brains were placed into an ice-cold matrix, and then sliced with a razor blade into 
coronal sections. Slices containing the PFCx (1 mm starting at 3.20 anterior the 
bregma) or AM (2 mm starting at 1.5 posterior the bregma) were obtained. 
Sample-punches of the PFCx (including prelimbic and infralimbic regions) and of 
the AM (including basolateral complex and central nucleus) were dissected under 
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stereomicroscope in accordance with rat brain atlas (Paxinos and Watson, 1986), 
frozen immediately on dry ice and stored at -80°C until analysis. 
 
 
 
 
ETOH = Ethanol 
 
Table 2. Description of the experimental design showing ETOH doses, treatments and tissue 
dissection timing for each group of study. 
 
Body weight of rats have been recorded daily (Table 3). 
 
 Body Weight (g : mean ± SEM)     
             
Groups Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 
veh 341 ± 6 336 ± 6 333 ± 7 333 ± 7 331 ± 8 329 ± 7 
EtOH 343 ± 4 330 ± 4 319 ± 5 308 ± 6 303 ± 8 301 ± 9 
 
 Day 7 Day 8 Day 9 Day 10 Day 11 Day 12 
veh 330 ± 6 331 ± 8 347 ± 9 352 ± 9 354 ± 9 357 ± 9 
EtOH 299 ± 6 297 ± 7 299 ± 9 304 ± 9 309 ± 9 315 ± 8 
 
SEM = standard error of the mean. 
 
Table 3. Bodyweight of rats subjected to 5-day intragastric administrations (three times per day) of 
water (vehicle) or EtOH, including withdrawal groups (total period 12 days). Results are expressed in 
grams (mean _ SEM). No significant differences between vehicleand EtOH-treated groups have been 
detected at any day. 
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3.1.2 Blood alcohol levels (BALs) 
 
For BALs, a separate set of rats (n = 7) was used. Blood was collected from the tail 
vein (0.5 ml) 30, 60, 120, 210, 300, 420, 540 minutes following a single EtOH 
administration of 3.0 g/kg and the first EtOH administration of 1.5 g/kg of the 
cumulative dose (1.5 g/kg three times at 1.5-hour intervals) and immediately frozen. 
EtOH levels were determined by gas chromatography (Schroeder, 1984). Samples 
were mixed with an internal standard of n-butanol, incubated for 60 minutes at 40°C 
and a 1-ml headspace aliquot was injected into an HRGC 5160 Mega series (Carlo 
Erba, Milan, Italy) containing a Phenomenex Zebron ZB-624 
(Phenomenex, Torrance, CA, USA). The analysis was performed isothermally at 
150°C with a constant pressure of 0.2 Kg/cm2 of Helium carrier gas. The inlet and 
detector temperature were kept at 200°C. EtOH peaks were identified and quantitated 
by comparison with a known standard. The blood EtOH concentrations are expressed 
in mg/dl. 
 
 
 
3.1.3 Behavioral measures 
 
Behavioral observations of intoxication and withdrawal were carried out by two 
operators independently and in blind fashion. 
 
 
 
3.1.3.1 Degree of Alcohol Intoxication  
 
Following the second alcohol or water administration, the degree of alcohol 
intoxication was assessed every day by using the following rating scale described by 
Majchrowicz (Majchrowicz, 1975): 
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 0 = Neutral : no signs of intoxication. 
1 = Sedation: reduced muscle tone, dulled appearance and slow locomotor activity, 
but no impairment of gait or coordination. 
2 = Ataxia 1: slight gait impairment and slight motor incoordination, but able to 
elevate abdomen and pelvis. 
3 = Ataxia 2: clearly impaired staggering gait and impaired motor coordination, 
some elevation of abdomen and pelvis. 
4 = Ataxia 3: slowed righting reflex, heavily impaired motor coordination, no 
elevation of abdomen and pelvis. 
5 = LORR: unable to right itself when placed on its back, other reflexes still present. 
6 = Coma: no signs of movement; no response to pain stimuli; no blinking reflex; 
spontaneous breathing. 
 
 
 
3.1.3.2 Measurement of physical signs of alcohol withdrawal 
 
The rats were then observed for 5 minutes 20 hours after the last EtOH 
administration. At each observation time, rats were assessed simultaneously for the 
following behavioral conditions: Each parameter was scored from 0 to 5 using a 
rating scale . 
	  
	  
	  
0=	  Agitation	  
1=	  Tail	  stiffness	  
2=	  Abnormal	  posture	  
3=	  Abnorml	  gait	  
4=	  Autonomic	  hyperactivity	  
5=	  Lack	  of	  exploratory	  behavior	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3.1.4 Real-Time quantitative reverse transcription-polymerase chain reaction 
(qRT-PCR) 
 
 
3.1.4.1 Extraction and measurement of total RNA 
 
Total RNA was prepared according to the method previously described 
(Chomczynski and Sacchi, 1987). The RNA was extracted from single tissue 
samples by homogenizing with TRI Reagent solution (Ambion Inc. Italy), containing 
phenol and guanidine thiocyanate (Ambion), 1 mL TRI Reagent solution per 50-100 
mg tissue. Then, 0.2 ml chloroform/2 ml of homogenate, and centrifuging the 
suspension at 12,000 x g for 10-15 minute at 4°C, and was transfered the aqueous 
phase to a fresh tube. A volume of 0.5 ml isopropanol was added, incubated for 15 
min at 4°C and the RNA pellet was isolated by centrifugation at 12,000 x g for 25 
min at 4°C. 
The pellet was washed twice with 75% ethanol, dried under vacuum and then 
resuspended in 25 µl of Rnase-free water. Total RNA, digested with DNase RNase-
free enzyme to eliminate genomic DNA content, was quantified by measurement of 
absorbance at 260 nm (1OD/ml = 40 µg RNA/ml). The ratio OD260/OD280 > 2 
provided an estimate of the purity of the total RNA. 
 
 
 
3.1.4.2 Reverse Transcription and PCR 
 
RNA samples were subjected to DNase treatment and converted to cDNA with the 
GeneAmp RNA PCR kit (Applied Biosystems, Foster City, CA, USA) by using 
random hexamers (0.45 µg of total RNA in a final reaction volume of 20 µl). The 
cDNAs were subsequently diluted three times.  
Relative abundance of each mRNA species was assessed by real-time RT-PCR 
employing 1 µl of the diluted samples in a final volume of 20 µl using iQ SYBR 
Green Supermix (Bio-Rad, Hercules, CA, USA) on an DNA Engine Opticon 2 
Continuous Fluorescence Detection System (MJ Research, Waltham, MA, USA). 
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To provide precise quantification of initial target in each PCR reaction, the 
amplification plot is examined and the point of early log phase of product 
accumulation is defined by assigning a fluorescence threshold above background 
defined as the threshold cycle number or Ct.  
Differences in threshold cycle number were used to quantify the relative amount of 
PCR target contained within each tube. Relative expression of different gene 
transcripts was calculated by the Delta-Delta Ct (DDCt) method and converted to 
relative expression ratio (2-DDCt) for statistical analysis (Pfaffl, 2001; Livak and 
Schmittgen, 2001). 
All data were normalized to the endogenous reference genes glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) expression. Results on RNA were normalized to 
results obtained on RNA from the control, vehicle treated rats. After PCR, a 
dissociation curve (melting curve) was constructed in the range of 60 ºC to 95 ºC to 
evaluate the specificity of the amplification products. The primers used for PCR 
amplification (Table 2) were designed using Primer 3. 
Total RNA was converted to complemetary DNA (cDNA) using 50 U Superscript II 
Reverse Transcriptase (Invitrogen, Milan, Italy) in 20 µL of buffer containing 0.5 
mM deoxynucleotide triphosphates (Invitrogen, Milan, Italy), 40 U RNase inhibitor 
(Invitrogen, Milan, Italy) and 0.5 µg Oligo (dT) 12-18 Primer (Invitrogen, Milan, 
Italy) (Table 4). 
 
 
          
FORWARD ( 5’- 3’) 
 
REVERSE  (3’- 5’) 
PRODUCT 
SIZE 	  GAPDH  AGACAGCCGCATCTTCTTGT 	  CTTGCCGTGGGTAGAGTCAT 	  207 	  BACT 	  ATCACGATCATGGCCCTCTACTCC 	  TGGTGGCAGTCTTCATCTTGGTGT 	  106 	  KOP 	  TTGGCTACTGGCATCATCTG 	  ACACTCTTCAAGCGCAGGAT 	  177 	  NOP 	  AGCTTCTGAAGAGGCTGTGT 	  GACCTCCCAGTATGGAGCAG 	  101 	  PDYN 	  CCTGTCCTTGTGTTCCCTGT 	  AGAGGCAGTCAGGGTGAGAA 	  157 	  PNOC 	  TGCAGCACCTGAAGAGAATG 	  CAACTTCCGGGCTGACTTC 	  170 
 
 
BACT = beta-actin; GAPDH = glyceraldehyde-3-phosphate dehydrogenase; KOP = kappa opioid 
receptor; NOP = nociceptin opioid receptor; PDYN = prodynorphin; PNOC = pronociceptin. 
 
Table 4. Primer sequences used for reverse-transcription-polymerase chain reaction 
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3.1.4.3 Statistical analysis 
 
Intoxication and withdrawal signs data, represented as total score, were analyzed by 
non-parametrical analysis (Mann–Whitney U-test). EtOH effects on genes expression 
alterations were statistically asnalyzed using the twotailed Student’s t-test. Statistical 
significance was set at P < 0.05. 
 
 
 
3.1.5 Epigenetic studies 
 
 
3.1.5.1 Analysis of histones modification by Chromatin Immunoprecipitation 
(ChIP) and Real Time PCR 
 
Chromatin was prepared from frozen tissues as previously described with minor 
modifications (Dahl and Collas, 2007): proteins were cross-linked to DNA by 
addition of formaldehyde at a final concentration of 1% in phosphate buffer saline 
(PBS) containing a broad-range protease inhibitor cocktail (PIC) (Roche) and 
butyrate (Sigma), for 8 min at room temperature. The cross-linking reaction was 
quenched by adding glycine to a final concentration of 0.125 M and incubating for 5 
min at room temperature, the sample washed, and lysed thorough resuspension by 
pipetting in 120 ul of lysis buffer.  
The sample was incubated on ice and sonicated for 30 s to shear the DNA to 
fragments ranging in size from 150 to 700 bp, as analyzed by agarose gel 
electrophoresis. 
The lysate was centrifuged at 12 000 g for 10 min at 4°C and the supernatant 
transferred into a chilled tube, leaving around 30 ul of buffer with the pellet. Another 
30 ul of lysis buffer was added and the tube vortexed. After centrifugation as before, 
50 ul of the supernatant was pooled with the first supernatant and sonicated for 
another 2 X 30 s on ice.  
After removing a few µl to serve as "input" DNA, for each immunoprecipitation, 8 
µg of chromatin was diluted 10-fold in RIPA buffer (10 mM Tris-HCl, pH 7.5, 1 mM 
EDTA, 0.5 mM EGTA, 1% Triton X-100, 0.1% SDS, 0.1% Na-deoxycholate, 140 
mM NaCl) containing PIC and incubated overnight by rotation with either no 
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antibody as control or with 1 - 4 µg of antibody, previously coated with Protein A 
beads (Invitrogen), for 2 hours at 4°C with agitation, against either H3K4me3 
(Abcam, ab8580), H3K27me3 (Millipore, 17-622), H3K9Ac (Millipore, 17-658). 
The beads and associated immune complexes were washed three times with RIPA 
buffer and once with Tris-EDTA buffer. The immune complexes were eluted with 
elution buffer (20 mM Tris-HCl, 5 mM EDTA, 50 mM NaCl) containing proteinase 
K (50 µg/ml) at 68°C for 2 hours, and DNA was recovered by phenol extraction, 
ethanol precipitated, and resuspended in 50 µl of sterile water. This procedure has 
been described in more detail (Dahl and Collas, 2007). Thereafter, real-time qPCR 
(RT-qPCR) quantification of the genomic sequences from regions in the rat PDYN 
and PNOC proximal promoter associated with the immunoprecipitated proteins were 
carried out. The primers used for PCR amplification were designed using Primer 3 
software (Rozen and Skaletsky, 2000): 
 
 
 
PDYN (from –348 to –175 bp)  
Forward (5′- ctgtctcctcccatctctgc) and the antisense primer: (5′- 
tagctgctccaggtgatgtg). 
 
PNOC (from –645 to –460 bp) 
Forward (5′- cagacagggaggacatggat) and the antisense primer: (5′- 
ggactgcaaagtgcagacaa). 
 
 
The relative abundance was assessed by RT-qPCR using iQ SYBR Green Supermix 
(Bio-Rad) on a DNA Engine Opticon 2 Continuous Fluorescence Detection System 
(MJ Research). 
To provide precise quantification of the initial target in each PCR reaction, the 
amplification plot was examined and the point of early log phase of product 
accumulation defined by assigning a fluorescence threshold above background, 
defined as the threshold cycle number or Ct.  
Differences in threshold cycle number were used to quantify the relative amount of 
the PCR targets contained within each tube. After PCR, a dissociation curve (melting 
curve) was constructed in the range of 60 ºC to 95 ºC (22) to evaluate the specificity 
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of the amplification products. The relative expression of different transcripts was 
calculated by the delta-delta Ct (DDCt) method and converted to relative expression 
ratio (2-DDCt) for statistical analysis (Livak and Schmittgen, 2001). 
All ChIP data were normalized to the input DNA amounts (Ct values of 
immunoprecipitated samples were normalised to Ct values obtained from 'input'). In 
addition, results on DNA from treated samples were normalized to results obtained 
on DNA from the control sample. Each ChIP experiment was repeated at least three 
times. 
 
 
3.1.5.2 DNA methylation 
 
In order to assess the possible methylation status of the promoter region of studied 
genes in  the rats treated with alcohol was performed: 
 
• DNA extraction  
• Bisulfite treatment of extracted DNA 
• Analysis of treated DNA by Real-Time PCR 
 
 
DNA extraction and purification  
 
DNA was extracted from samples of rat brain, which have been moved at <-20 ° C 
for several days before extraction to facilitate lysis leukocytes. FlexiGene (Quiagen) 
was used to extract genomic DNA following manufacterer’s instuctions which main 
steps are mentioned below. 
 
1.  To FG1 Buffer (lysis), contained in 50 ml falcon tube, add 7 ml of whole 
blood and vortex to mix well. 
2. Centrifuge 2500 rpm for 30 min at 10°C. Centrifugation separate proteins 
(and other macromolecules and sub cellular structures) according they 
dimensions (and form) through generation of gravitational forces within a 
sample tube. 
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3. Surnatant is discarded and FG2 Protease Buffer (denaturation buffer) is added 
and inmediatly vortexed, the resulting volume is then divided in 1,5 ml 
eppendorf. 
4. Incubate aliquots at 65° for 10 min: color changes from red to green when 
proteic digestion verifies. 
5. Add isopropanol (100%) and mix until DNA precipitation. 
6. Centrifuge 10000 rpm for 10 min at room temperature and discard surnatant. 
7. Add ethanol 95 % and vortex 5 seconds. 
8. Centrifuge 10000 rpm for 10 min at room temperature and discard surnatant. 
9. Dry DNA pellet at room temperature until full diluent evaporation (at least 5 
min). 
10. Add FG3 Buffer (hydratation buffer), vortex 5 seconds at low speed, 
resuspend the DNA pellet and incubate for 1 hour at 65°C bath. 
 
Sample DNA amount was determined by spectrophotometry at 260 nm and DNA 
aliquots were frozen at -20°C. 
 
 
 
Sodium Bisulfite treatment 
 
The vast majority of DNA methylation analysis is based on using a PCR using DNA 
treated with sodium bisulphite as a model. Two different strategies are used in the 
design of the primers for these reactions:  
 
• Methylation-indipendent PCR primers (MIP) 
• Methylation-specific PCR primers (MSP) 
 
Normally, the epigenetic information is lost during the PCR because the DNA 
polymerase does not distinguish between methylated and non-methylated cytosine, 
so the polymerase adds a guanine and then a non-methylated cytosine in both 
situations. After PCR, each originally methylated allele is diluted to a concentration 
impossible to analyze, so the DNA must be modified in a way that allows methylated 
information to remain preserved. Treatment with sodium bisulfite, which deaminates 
cytosine into uracil (Clark et al., 1994) is the method of choice in most laboratories 
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for this type of analysis. Due the fact that the degree of deamination of 5'-
methylcytosine to thymine is much slower than the conversion of cytosine to uracil, 
it is assumed that the only remaining cytosine after treatment with sodium bisulfite 
are those derived from 5'metilcitosine. Thus, during the subsequent PCR, the uracil 
residues are transcribed as cytosine. 
The procedure is based on the chemical reaction of single-stranded DNA with 
sodium bisulfite (HSO3-) at low pH and high temperatures. 
The chemical reaction of each step is as follows: cytosine carbon-6 sulfonation, 
irreversible hydrolytic deamination of carbon-4 that produces a sulfonate uracil, and 
finally the following desulfonation under alkaline conditions to generate uracil.  
Methylation of carbon-5 prevents the carbon-6 sulfonation in the first step reaction. 
Although the 5-methylcytosine can react with sodium bisulfite, this reaction is 
extremely slow, and the balance favors the 5-methylcytosine rather than thymine (the 
deamination product of 5-methylcytosine). 
Thus it is important the subsequent necessary purification to remove salts and other 
reagents used in the process.  Treatment with sodium bisulfite converts unmethylated 
cytosine of the original strand of DNA to uracil, while methylated cytosines remain 
cytosines. The CpG dinucleotide is the target of methylation in human cells (Figure 
27). 
 
 
 
 
Fig. 27. Sodium Bisulftine treatment of Genomic DNA 
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The protocol described by Frommer et al 1992 has been widely used for the 
treatment with sodium bisulfite. When treatment with sodium bisulfite is conducted 
under appropriate conditions, the expected convertion level of unmethylated 
cytosines is about 99% (Taylor et al., 2007). 
Despite this high level of conversion, however, it is possible that a small amount of 
DNA have a lower conversion rate (Warnecke et al., 2002) and the distribution of 
unconverted sites does not be random, so some promoter regions are more prone to 
an incomplete conversion. The conversion rate depends greatly on the quality of 
DNA (Warnecke et al., 2002).  
This is especially important to keep in mind when looking for low levels of DNA 
methylation with MSP primers based methods. 
 
The antiparallel strands of DNA are no longer complementary after treatment with 
sodium bisulfite. Therefore, the MIP and MSP primers are designed to be both 
Forward and Reverse. 
In mammalian DNA, the major base modification is 5-methylcytosine (5-MC), this 
occurs in 2-5% of all cytosine residues (generally those that are found in CpG 
doublets). The modification with bisulfite is a reaction between the molecule 
bisulfite and unmodified cytosine of single-stranded DNA. The reaction converts 
cytosine into uracil, while methylated cytosine (5-MC) within the CpG sites remains 
unchanged. The modified DNA can be amplified via PCR to understand the state of 
methylation.  
The bisulfite modification of DNA samples was carried out with the EpiTect bisulfite 
kit (Zymo) (Figure 28) as described by the manufacturer. For each conversion 
reaction 1 ug of DNA was used. After conversion, the modified DNA was purified 
and eluted in 20 ul of TE (2,5 mmol / L EDTA, 10 mmol / L Tris-HCl (pH 8)), then 
used immediately or stored at -20 ° C for one month. Positive control (100%) and 
standard curves were produced using universally methylated (uDNA) and methylated 
(mDNA) DNA. 
 
 
 
 
 70 
DNA Input: each treated sample have 500 ng of DNA 
Conversion efficiency: >99% of unmethylated Cytosines are converted to Uracil 
NA Recovery: >80% 
 
 
• Add 5uL of M-Dilution Buffer to DNA sample. Add Nuclease-Free water to 
a final volume of 50µL. 
 
• Incubate 15 min at 37°C, and add 100µL of CT Conversion Reagent to each 
sample. Incubate for 12 to 16 hours at 50°C. 
 
• At the end of incubation time, transfer each sample to individual separation 
columns, containing 400µL of M-Binding Buffer. After the first 
centrifugation, the DNA remains attached to the resin present in the column 
while the buffer is discarded. 
 
• Add M-Desulphunation Buffer and incubate 15-20 min. 
 
• Add M-Wash Buffer and centrifuge to wash the DNA. 
 
• Add 20 µL of M-Elution Buffer to release DNA from the resin. 
 
 
Converted DNA can be conserved at -80° for up to three months. 
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Fig. 28. EZ DNA Methylation procedure (source ZIMO RESEARCH 2010). 
 
 
MSP primers 
 
The MSP primers are designed to amplify only the methylated DNA thus the 
possible errors associated with MIP based methods are no longer a problem. This 
specificity is achieved by including a few CpG sites in the sequence of the primer, 
preferably at the 3’ end (Figure 29) (see Table 5 for MSP primers). 
If PCR strict conditions are followed, only the amplification of methylated DNA will 
occurs.  
MSP assays are generally associated with high levels of false positives, especially 
when using large numbers of PCR cycles, which are often necessary to obtain high-
sensitivity analytical assays. 
False-priming events (in which the amplification takes place despite the mismatch 
between primer and sample) and not fully converted DNA molecules may be 
responsible for false-positive results. 
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The events of false-priming can be detected through the use of an appropriate 
negative control and prevented by limiting the number of cycles and using higher 
annealing temperatures. 
The present study analyzes four genes PDYN, PNOC and BACT. We also used 
MYOD noCpG. Of each of these genes we create their MSP primers in order to 
perform MSP Real-Time PCR. 
After retrieving the correct sequence of special databases of the gene of interest, we 
look upstream in the promoter region for CpG rich areas (CpG Island). Several pairs 
of suitable sequences are tested (forward / reverse primers). 
 
 
 
 
 
 
 
 
 
 
Fig. 29. Graphic representation of CpG rich areas (CpG Island) within gene promoter region. 
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MSP primers 
PDYN:    
Forward 5’- TTTTATAGTTTAATTACGTAAAGTCGT -3’ 
Reverse 5’- AACTCATTACATACCTCATACAACCG -3’ 
PNOC:   
Forward 5’- TTTTTGAAATTTAAGGGTTTATTTC -3’ 
Reverse 5’- AATTTACTACACTCCAATAACYGAT -3’ 
BACT:    
Forward 5’- TTTTGAATTTGGGGGTGTGT -3’ 
Reverse 5’- AAAACCAAACCAACTTCCTTATTCT -3’ 
 
 
Table 5. Sequence of MSP primers used for MSP RT-PCR. 
 
 
 
 
MSP Real-Time PCR 
 
For the methylation PCR study, a SYBR Green PCR kit was used. Each 20 ul of 
PCR reaction contains: 2 ul of eluted bisulfite modified DNA, 10 ul of SYBR Green 
PCR Master Mix, 1 ul of each of the two primers (concentrations used vary from 10 
to 100 pmol / ul resulting in final concentrations of 0.3 to 3 uM), and 6 ul of DNase-
free water. 
To normalize for the amount of input DNA, we have chosen a pair of primers 
corresponding to a specific sequence of MyoD gene. Real-time PCR conditions were 
95 ° C for 15 minutes followed by 45 cycles of 94 ° C for 15 s, 60 ° C for 30 s, 72 ° 
C for 30 s with data acquisition after each cycle. At the end, the amplification 
products will be verified by melting curve analysis: 95 ° C for 1 min, 55 ° C for 1 
min, followed by 80 cycles of increasing incubation temperature for 10 s each, from 
55 ° C to up to 95 ° C (0.5 °C increase) with data acquisition after each cycle. Two 
replicates for each sample were used and PCR was performed in a DNA Engine 
Opticon 2 continuous fluorescence detection system (MJ Research, Waltham, MA, 
USA). 
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Ct values of each sample were recorded. Methylation percentage was calculated by 
2^(-DDCT), where DDCT = (Ct Target - Ct, MyoD) sample - (Ct Target - Ct, 
MyoD) fully methylated DNA and multiplied by 100. 
A calibration curve using the fully methylated DNA was carried out in parallel with 
each analysis, providing additional confirmation for each sample as methylation 
ratio, defined as the ratio of the fluorescence emission intensity values of target PCR 
product respect those of Myod PCR products.  
The correct length and purity of PCR products were verified by agarose gel 
electrophoresis (1,5% agarose). 
 
 
 
 
3.5.1.3 Statistical Analysis 
 
EtOH effects on histone modification and DNA methylation alterations were 
statistically analyzed using the two-tailed Student’s t- test. Statistical significance 
was set at p<0.05.  
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3.2 Heroine studies in human abusers 
  
 
3.2.1 Reagents 
 
The antibody directed against the MOR was obtained from GeneTex, Inc. (Irvine, 
CA). The antibody directed against βarrestin1 was obtained from Epitomics, Inc. 
(Burlingame, CA). Antibodies directed against phospho-MOR, ERK1/2, phospho-
ERK1/2, Elk-1 and phospho-Elk-1 were all obtained from Cell Signaling 
Technology, Inc. (Danvers, MA).  
The antibody directed against GAPDH was obtained from Millipore (Billerica, MA). 
The antibody directed against MEK1 was obtained from Invitrogen Corporation 
(Carlsbad, CA). Antibodies directed against β arrestin2 and MEK2 were obtained 
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA).  
 
 
 
 
3.2.2 Methods 
 
3.2.2.1 Human Brain Specimens 
 
Postmortem brains were obtained from either the Forensic Medicine Department of 
Semmelweis University (Budapest, Hungary) or from the Forensic Medicine 
Department of Karolinska Institutet (Stockholm, Sweden) under approved ethical 
guidelines. All cases were from Caucasians and had a postmortem interval < 24 hrs. 
The subjects were sorted into two case groups: those that died from heroin overdose 
(heroin group) and normal control subjects without head trauma (control group).  
All of the subjects were evaluated for common drugs, including alcohol, barbiturates, 
benzodiazepines and phenycyclidine. 
A total of four subjects tested positive for ethanol toxicity, three in the heroin and 
one in the control group, but none of these subjects showed signs of chronic alcohol 
abuse. Most of the subjects in the heroin group had a prior history of heroin abuse 
and also had physical signs of abuse such as needle track marks at time of autopsy. 
Furthermore, these subjects also exhibited a positive toxicology for heroin and/or its 
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metabolites, such as 6-monoacetylmorphine (6-MAM), morphine and morphine 
glucuronide. In contrast, the subjects in the control group had negative toxicology for 
opiates.  
The heroin subjects used in this study were predominantly heroin users that had no 
history of methadone or buprenorphine clinical treatment and were negative for 
human immunodeficiency virus (HIV) infection.  
These subjects therefore represent a unique population of drug abusers that can be 
utilized to study the long-term effects of heroin use on the biochemical and molecular 
alterations that occur in the human brain. 
 
 
 
 
3.2.2.2 Brain Punches 
 
The tissue (average weight of 200 mg) was punched from the putamen of 48 
postmortem human brains and kept at -80oC. The tissue punches were pulverized into 
a fine powder using a Bio-pulverizer (Biospec Products Inc.) on dry ice, mixed and 
then aliquoted into eppendorf tubes that were kept at -80oC until either protein was 
isolated. 
 
 
 
 
3.2.2.3 Western Blotting 
 
For each brain, between 10-20 mg of pulverized human putamen brain was 
homogenized on ice in modified RIPA buffer (1% IGEPAL CA-630, 1% sodium 
deoxycholate, 0.1% SDS, 0.15 M NaCl, 0.01 M sodium phosphate, pH 7.2) with 5 
mM DTT, 1 µg/ml leupeptin, complete protease inhibitor cocktail with EDTA 
(Roche) and Halt™ phosphatase inhibitor cocktail (Thermo Scientific) using a 
dounce homogenizer (Kimble-Kontes), incubated at 4oC for 20 min and then 
centrifuged at 15,000 g for 15 min at 4oC. The protein concentrations of the 
supernatants were determined by using the BCA protein assay (Thermo Scientific). 
An initial test gel was performed for each of the antibodies utilized in this study to 
confirm that there was a linear relationship between the amount of protein loaded 
onto the gel and the detection of that protein. A total of approximately 12µg was 
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resuspended in Laemmli buffer and analyzed on SDS-PAGE gels (Bio-Rad) and 
transferred to Protran® nitrocellulose membranes (Whatman).  
The membranes were stained for protein using Memcode (Thermo Scientific), scanned 
and then blocked overnight at 4oC using 50% Odyssey blocking buffer (Li-COR) diluted in 
PBS with gentle shaking. 
Primary antibodies were diluted in Odyssey blocking buffer with 0.1% Tween-20 
and incubated overnight at 4oC with gentle shaking. The membranes were washed six 
times, 5 min each, in PBS with 0.1% Tween-20 (PBST) at room temperature with 
gentle shaking. Secondary antibodies of either goat anti-rabbit or goat anti-mouse 
IRDye 680CW or IRDye 800CW (Li-COR) were diluted 1:5000 in Odyssey buffer 
with 0.1% Tween-20 and 0.01% SDS and incubated for 1 hour at room temperature 
with constant shaking.  
The membranes were washed another six times, 5 mins each, in PBST. Membranes 
were imaged using the Odyssey infrared imaging machine and the blots analyzed 
using ImageJ software. 
 
 
3.2.2.4 Statistical Analysis 
 
Values derived from densitometric analysis using ImageJ software were normalized 
to total protein levels as determined by staining nitrocellulose membranes with 
Memcode protein stain. Data for the heroin subjects were calculated with respect to 
control subjects (100%). In order to determine normal distribution of the data, a 
Shapiro-Wilk W test was performed.  
Either a square root or logarithmic transformation was performed in order to render 
non-normal distributions into normally distributed data.  
A general linear stepwise regression analysis was used to calculate statistical 
significance and to identify possible covariates. Variables included in the analysis 
were: age, sex, PMI, brain pH, ethanol toxicity and storage time. A Student’s t-test 
was used when no covariates were found. Spearman’s correlation coefficients were 
calculated to assess the relationship between protein levels and also to identify 
correlations with toxicology. Statistical tests were carried out using JMP (v 7.0.1; 
SAS Institute Inc.) and all results are expressed as mean ± SEM. 
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4. RESULTS  
 
 
4.1  Ethanol results in animals model  
 
 
4.1.1 Estimation of BALs 
 
Single or repeated EtOH binge intoxication induced BALs in the range of 350–450 
mg/dl and thus was clearly pharmacologically active. During binge treatment, the 
highest BAL (450 mg/dl) was reached after 30 minutes following the third 
administration and decreased to the level 120 mg/ml after 9 hours. A single dose 
caused a BAL of 350 mg/dl 1 hour after the administration and decreased to non-
pharmacologically level after 9 hours (Figure 30) (D’Addario et al., 2011b). 
 
 
 
 
 
 
 
Fig. 30.  Blood alcohol levels (BAL; mg/dl; mean_standard error of the mean) observed in the rat 
after intragastric single (3 g/kg) or repeated (3 x 1.5 g/kg) EtOH administration. 
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4.1.2 Behavioral changes during EtOH intoxication and withdrawal  
 
 
 
4.1.2.1	  Intoxication	  rating	  
	  
EtOH-induced intoxication in animals starting from the first binge administration 
(score: 2.7 ± 0.35 overall; Mann–Withney U = 0, P < 0.0002; Figure 31 ) and 
reached the maximum peak at Day 2 (score: 4.0 ± 0.27 overall; U = 0, P < 0.0002; 
Figure 31). Intoxication signs decreased over Day 3 (rate: 3.27 ± 0.4 overall; U = 0, 
P < 0.0002; Figure 31) and 4 (score: 2.3 ± 0.3 overall; U = 6, P < 0.01; Figure 31 ) 
and disappeared over Day 5 (score: 0.4 ± 0.2 overall; U = 13, P = 0.07; Figure 31). 
Control animals showed no signs of intoxication in all days (score: 0.45 ± 0.09 
overall ) (D’Addario et al., 2011b). 
 
 
 
 
 
Fig. 31. Intoxication score in ethanol administered rats. Intoxication rating, assessed every day 
following the second alcohol or water (veh) administration, is shown across the 5 days of binge-like 
EtOH administration. Mann–Withney U test **P < 0.01 and ***P < 0.001 versus control group. 
 
 
 
 
 
 
 80 
4.1.2.2	  Signs	  of	  alcohol	  withdrawal	  	  
	  
EtOH-treated rats showed significant withdrawal signs (compared with vehicle-
treated rats), measured 20 hours after each final daily EtOH treatment (Figure 32). 
The sum of  the observation scores [agitation, tail stiffness, abnormal posture, 
abnormal gait, autonomic, hyper-reactivity, no rearing (Uzbay et al., 1997)] 
progressively increased from 0 on Day 1 to 12.5 ± 0.4 on Day 6 (Mann–Withney U = 
0, Z = 3.3, P < 0.001; Figure 32), with significant differences between the 
experimental groups on Day 4 (U = 6, Z = 2.3, P < 0.02), Day 5 (U = 0, Z = 2.4, P = 
0.02), Day 7 (U = 0, Z = 2.6, P < 0.006), Day 8 (U = 0, Z = 2.7, P < 0.006), Day 9 (U 
= 0, Z = 2.4, P < 0.01), Day 10 (U = 0, Z = 2.6, P < 0.009) confirming the presence 
of significant overall withdrawal severity. Body weight of rats subjected to 
intragastric administrations was recorded daily up to Day 12 (W-7D group). A slight 
weight reduction in both vehicle- and EtOH-treated groups has been observed every 
day up to Day 8, recovering thereafter until the end of the experiment (Day 12). No 
significant differences were observed between the experimental groups (D’Addario 
et al., 2011b). 
 
 
 
 
 
Fig. 32. Withdrawal  score in ethanol administered rats. Alcohol withdrawal total score evaluated 20 
hours after the last administration of EtOH or water and up to 12 days. Mann–Withney U tests 
confirmed that withdrawal signs occurred in EtOH treated rats starting on Day 4 up to Day 10 after 
EtOH binge administration. *P < 0.02 and **P < 0.01 versus control group. 
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4.1.3 Gene expression studies 
 
 
4.1.3.1 PDYN/KOP System  
 
In the AM, gene expression studies revealed a significant increase in the levels of 
PDYN in the group of animals treated for 1 day (1D group) (3.194 ± 0.865 versus 
control group equal to 1, unpaired t-test: **P < 0.01; F(6, 6) = 2.430) returning to 
values comparable with control in the 5D group, and showing again an up-regulation 
in the W-1D group [1.7 ± 0.07, unpaired t-test: *P < 0.05; F(5, 4) = 7.061] (Figure 
33a) (D’Addario et al., 2011b). 
 
a) AM 
 
 
 
 
Fig. 33a. Levels of PDYN mRNA in the AM of rats treated with EtOH intragastrically (total daily 
dose: 4.5 g/kg/day) for 1 day (1D group) or 5 days (W-1D,W-3D,W-7D groups) in comparison with 
their respective control groups (CONT), see Materials and Methods section for details. Bars represent 
2-DDCt value calculated by Delta-Delta Ct (DDCt) method of seven rats for each group. Expression 
was normalized to glyceraldehyde-3-phosphate dehydrogenase and means of mRNA levels are 
expressed relative to control rats_standard error of the mean. Differences among treatments were 
estimated by t-test. *P < 0.05 and **P < 0.01 versus control group. 
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In the PFCx after 1 day of treatment with EtOH, PDYN mRNA was increased [1D 
group: 1.760 ± 0.262, unpaired t-test: *P < 0.05; F(5, 6) = 4.248], whereas no 
changes were evident in the other groups (Figure 33b) (D’Addario et al., 2011b). 
 
 
b) PFCx 
 
 
 
Fig. 33b. Levels of PDYN mRNA in the PFCx of rats treated with EtOH intragastrically (total daily 
dose: 4.5 g/kg/day) for 1 day (1D group) or 5 days (W-1D,W-3D,W-7D groups) in comparison with 
their respective control groups (CONT), see Materials and Methods section for details. Bars represent 
2-DDCt value calculated by Delta-Delta Ct (DDCt) method of seven rats for each group. Expression 
was normalized to glyceraldehyde-3-phosphate 
dehydrogenase and means of mRNA levels are expressed relative to control rats_standard error of the 
mean. Differences among treatments were estimated by t-test. *P < 0.05 and **P < 0.01 versus 
control group. 
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Levels of the KOP mRNA transcript in the AM show an increase after 5 days of 
treatments [1.71 ± 0.16, unpaired t-test: *P < 0.05; F(6,6) = 1.690] (Table 6). In the 
PFCx alterations in KOP gene expression were not observed (Table 6) (D’Addario et 
al., 2011b). 
 
 
 
 
 
KOP   
  1D 5D W-1D W-3D W-7D 
AM 1,04 ± 0,33 1,71 ± 0,16 ** 0,83 ± 0,29 1,08 ± 0,26 0,88 ± 0,15 
PFCx 0,89 ± 0,16 0,62 ± 0,13 0,6 ± 0,05 0,91 ± 0,13 1,01 ± 0,10 
 
 
 
Table 6. Quantitative reverse-transcription-polymerase chain reaction results. Relative KOP gene 
expression levels in AM and PFCx of rats orally administered with ethanol up to 5 days. Expression 
was normalized to glyceraldehyde-3-phosphate dehydrogenase and means of mRNA levels are 
expressed relative to control animals ± standard error of the mean. ** Indicate a significant difference 
from control group, P< 0.01 (t-test). 
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4.1.3.2 PNOC/NOP System  
 
In the AM levels of the PNOC mRNA transcript in the AM were significantly 
increased in the 1D group [2.298 _ 0.479, unpaired t-test: *P < 0.05; F(6, 6) = 5.325] 
and continues to increase with the progression of the treatment (5D group) becoming 
even higher [2.827 ± 0.403, unpaired t-test: **P < 0.01; F(6, 6) = 3.778]. When the 
animals were kept in abstinence, the levels of peptide mRNA were still significant 
high in the W-1D group [2.211 ± 0.259, unpaired t-test: *P < 0.05; F(5, 5) = 1.558] 
(Figure 34a) (D’Addario et al., 2011b). 
 
a) AM 
 
 
 
 
 
 
Fig. 34a. Levels of PNOC mRNA in the AM of rats treated with EtOH intragastrically (total daily 
dose: 4.5 g/kg/day) for 1 day (1D group) or 5 days (5D,W-1D,W-3D,W-7D groups) in comparison 
with their respective control groups (CONT), see Materials and Methods section for details. Bars 
represent 2-DDCt value calculated by Delta-Delta Ct (DDCt) method of seven rats for each group. 
Expression was normalized to glyceraldehyde-3-phosphate 
dehydrogenase and means of mRNA levels are expressed relative to control rats_standard error of the 
mean. Differences among treatments were estimated by t-test. *P < 0.05 and **P < 0.01 versus 
control group. 
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Conversely, in the PFCx we did not observe significant changes in the expression of 
PNOC (Figure 34b) (D’Addario et al., 2011b). 
 
 
b) PFCx 
 
 
 
 
Fig. 34b. Levels of PNOC mRNA in PFCx of rats treated with EtOH intragastrically (total daily 
dose: 4.5 g/kg/day) for 1 day (1D group) or 5 days (5D,W-1D,W-3D,W-7D groups) in comparison 
with their respective control groups (CONT), see Materials and Methods section for details. Bars 
represent 2-DDCt value calculated by Delta-Delta Ct (DDCt) method of seven rats for each group. 
Expression was normalized to glyceraldehyde-3-phosphate 
dehydrogenase and means of mRNA levels are expressed relative to control rats_standard error of the 
mean. Differences among treatments were estimated by t-test. *P < 0.05 and **P < 0.01 versus 
control group. 
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Moreover, no changes in NOP mRNA were detected in both the AM and PFCx 
(Table 7) (D’Addario et al., 2011b). 
 
 
NOP   
  1D 5D W-1D W-3D W-7D 
AM 1,02 ± 0,18 1,35 ± 0,13 1,32 ± 0,15 0,87 ± 0,19 0,84 ± 0,11 
PFCx 1,27 ± 0,11 1,07 ± 0,05 1,06 ± 0,10 1,12 ± 0,12 0,78 ± 0,17 
 
 
Table 7. Quantitative reverse-transcription-polymerase chain reaction results. Relative NOP gene 
expression levels in AM and PFCx of rats orally administered with ethanol up to 5 days. Expression 
was normalized to glyceraldehyde-3-phosphate dehydrogenase and means of mRNA levels are 
expressed relative to control animals ± standard error of the mean.  
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4.1.4 Histone modifications 
 
 
Sprague Dawley rats have administered with repeated binge EtOH intoxication to 
investigate whether alcohol could evoke epigenetic changes (histone modifications) 
in the PDYN and PNOC promoter regions associated with the different previously 
demonstrated genes up-regulation in the AM complex (Figure 35). 
 
 
 
 
 
 
Fig. 35. Sequences of rattus norvegicus PDYN and PNOC promoter regions. The transcriptional start 
site (+1) is indicated. The TATA box on PDYN promoter and the CRE sequence on PNOC promoter 
are also indicated and highlighted. Primer sequences are underlined indicating also the starting 
positions. 
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Group 1D 
 
In the AM, we found in the animals treated for 1 day with EtOH (1D group) a 
significant decrease of  H3K27me3 in both PDYN (0,45 ± 0,09 versus CONT group 
= 1, p< 0,05) and PNOC (0,46 ± 0,11 versus CONT group = 1, p < 0,05) promoter 
regions as well as a significant increase in H3K9Ac for PDYN promoter (1,7 ± 0,3, p 
< 0,05) and for PNOC promoter (1,8 ± 0,26, p < 0,05) (Figure 36). 
 
 
1 D Group 
  
 
               a) PDYN promoter                                     b) PNOC promoter 
 
     
 
 
Fig. 36. RT-qPCR analyses of H3K27me3, H3K9Ac and H3K4me3 immunoprecipitated DNA 
fragments at a)PDYN and b)PNOC promoters. ChIP showing the levels of specific histone 
modification normalized to total input DNA in rats treated with EtOH intragastrically (total daily 
dose: 4.5 g/kg/day) for 1 day (1D group, n = 7) or vehicle (cont, n =7). Data are expressed as means ± 
SE of triplicate independent samples.*P < 0.05 vs. control; t-test. 
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Group 5D 
 
In the AM, we found in the animals treated for 5 days (5D group) a significant  
increase of H3K9Ac in PNOC promoter (2,4 ± 0,67, p < 0,05) (Figure 37); no 
significant alteration we found for other histone modification analyzed. 
No changes we observed in PDYN promoter region. 
 
 
5 D Group 
 
 
              a) PDYN promoter                                       b) PNOC promoter 
 
 
 
         
 
 
 
Fig. 37. RT-qPCR analyses of H3K27me3, H3K9Ac and H3K4me3 immunoprecipitated DNA 
fragments at a) PDYN and b) PNOC promoters. ChIP showing the levels of specific histone 
modification normalized to total input DNA in rats treated with EtOH intragastrically (total daily 
dose: 4.5 g/kg/day) for 5 day (5D group, n = 7) or vehicle (cont, n =7). Data are expressed as means ± 
SE of triplicate independent samples.*P < 0.05 vs. control; t-test. 
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Group W-1D 
 
In the AM, in contrast, we did not observe any histone modifications changes in the 
W-1D group in both genes promoter. Moreover, EtOH exposure did not induce any 
statistically significant alteration of H3K27me3, H3K9ac and H3K4me3 (Figure 38).  
 
 
W-1D Group 
 
 
                a) PDYN promoter                                 b) PNOC promoter 
 
 
 
          
 
 
 
Fig. 38. RT-qPCR analyses of H3K27me3, H3K9Ac and H3K4me3 immunoprecipitated DNA 
fragments at a) PDYN and b) PNOC promoters. ChIP showing the levels of specific histone 
modification normalized to total input DNA in rats treated with EtOH intragastrically (total daily 
dose: 4.5 g/kg/day) for 5 day and 1 day of withdrawal (W-1D group, n = 7) or vehicle (cont, n =7). 
Data are expressed as means ± SE of triplicate independent samples. 
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4.1.5 DNA Methylation 
 
 
 
Sprague Dawley rats have administered with repeated binge EtOH intoxication to 
investigate whether alcohol could evoke epigenetic changes (DNA methylation) in 
the PDYN and PNOC promoter regions associated with the different previously 
demonstrated genes up-regulation in the AM complex 
The analyses of DNA methylation in PDYN and PNOC promoters didn’t show a 
significative alteration (Table 8).  
 
 
 
 
Table 8. DNA METHYLATION LEVELS AT GENE PROMOTERS : % of DNA methylation in 
promoter regions of PDYN and PNOC in rats treated with vehicle or EtOH intragastrically (total day 
dose : 4.5g/kg/day) for 1 day (1D group) or for 5 days (5D group, W-1D). 
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4.1  Heroin results in Human abusers 
 
 
 
4.1.1 Regulation of MAPK signaling components in the brains of heroin 
addicts 
 
One of the key intracellular pathways activated by MOR is the MAPK pathway. 
To determine whether there are perturbations in protein levels of the MAPK 
pathway as a consequence of chronic heroin abuse, we focused on the core 
components of the pathway including MEK1/2 and ERK1/2. In the putamen of 
heroin addicts, the protein expression of MEK1 was significantly reduced (91.28 
± 2.55%, p < 0.05; F 1,41 = 4.33; Figure 39a), whereas MEK2 was also lower but 
not significantly changed (91.43 ± 4.29%; Figure 39b).  
 
 
 
                           a) MEK1                                                b) MEK2 
 
 
 
Fig. 39. Protein levels of  a) MEK1  b) MEK2 in the putamen of control subjects and heroin 
abusers. Results are expressed as mean ± SEM with respect to control subjects (100%). * P < 
0.05.  
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Of the two known targets of the MEK1/2, we observe a significant decrease in 
the protein level of ERK1 (84.78 ± 3.83%, p < 0.05; F 1,46 = 4.40; Figure 40a). 
Conversely, there is a significant increase in the protein levels of ERK2 (111.78 
± 2.32%. p < 0.005; F 1,44 = 9.33; Figure 40b).  
 
 
 
                           a) ERK1                                                b) ERK2 
 
 
 
Fig. 40. Protein levels of  a) ERK1 b) ERK2 in the putamen of control subjects and heroin 
abusers. Results are expressed as mean ± SEM with respect to control subjects (100%). * P < 
0.05, ** P < 0.01.  
 
 
 
Dual phosphorylations of the ERKs are required for their full activation and for 
their ability to mediate a variety of cellular functions, including activation of 
downstream transcription factors. In the putamen of heroin addicts, the level of 
phosphorylated ERK1 (105.67 ± 13.01%; Figure 41a) and phosphorylated ERK2 
(120.1 ± 11.4%; Figure 41b) was not significantly changed when compared with 
control subjects.  
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                          a) pERK1                                               b) pERK2 
 
 
Fig. 41. Protein levels of  a) pERK1 b) pERK2 in the putamen of control subjects and heroin 
abusers. Results are expressed as mean ± SEM with respect to control subjects (100%). 
 
 
 
 
4.1.2 Regulation of Elk-1 in the brain of heroin addicts 
 
The well-characterized transcription factors Ets-like protein-1 (Elk-1) has been 
implicated in the cellular responses of opioids and is a nuclear targets for 
activated ERK1/2. Elk-1 is directly phosphorylated by ERK1/2, and once 
activated forms a ternary complex on serum response elements (SREs) that 
activate immediate early genes such as c-fos. In the putamen of heroin addicts, 
the protein expression of Elk-1 was significantly increased (133.26 ± 8.21%, p < 
0.01; F 1,46 = 7.38; Figure 42a). However, there is a significant reduction in the 
level of phosphorylated Elk-1 (86.92 ± 3.35%, p < 0.05; F 1,41 = 5.21; Figure 42b) 
in the putamen of heroin addicts. 
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a) ELK1                                               b) pELK1 
 
 
 
 
 
 
Fig. 42. Protein levels of  a) ELK1 b) pELK1 in the putamen of control subjects and heroin 
abusers. Results are expressed as mean ± SEM with respect to control subjects (100%). * P < 
0.05, ** P < 0.01.  
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5. DISCUSSION 
 
 
 
5.1 ALCOHOL  
 
 
5.1.1 Gene expression  
 
It is generally difficult to clearly understand whether changes in them RNA levels 
reflect a possible involvement of a specific gene in the execution of a behavior (i.e. 
alcohol intake) or the effect of alcohol by itself on this particular gene. Because 
prolonged exposure to EtOH by itself changes the expression of several genes (Worst 
et al., 2005), the main goal of our study was to try to correlate the effects of different 
exposure to EtOH on opioid genes expression using a direct administration protocol. 
The majority of studies describing the EtOH effects utilized different protocols of 
administrations such as forced drinking (Schulz et al., 1980), liquid diet (Seizinger et 
al., 1983), injection procedures (Lindholm et al., 2000), placement in a vapor 
chamber (Zapata and Shippenberg, 2006) or using a genetically selected line for high 
alcohol drinking behavior (Arlinde et al., 2004).  
A clear distinction between the role of a specific gene in drinking behavior or in 
EtOH effect is still confounding; thus, we decide to use binge intragastric protocol to 
minimize the potential confounding factors induced by EtOH administration in rats.  
The first main result of the present study is that the experimental conditions used 
were able to evoke tolerance to alcohol effects and dependence in rats, as measured 
by the progressive decrease of intoxication signs and the occurrence of clear 
withdrawal signs, respectively. Our results are thus consistent with very recent 
published data showing that this is a reliable methodology that effectively induces 
physical dependence upon EtOH over a short time period (Braconi et al., 2010). 
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Changes in PDYN/KOP system gene expression 
 
Many of the studies examining dynorphinergic system activity following exposure to 
alcohol (Przewlocka et al., 1997; Rosin et al., 1999; Lindholm et al., 2000) reported 
inconsistent results probably arising from the various paradigm of administration 
used and experimental models, but also for the complex role of this system.  
Here, we observed an up-regulation of PDYN mRNA following a single day of 
EtOH administration in both the brain region investigated, the AM and the PFCx. 
Acute EtOH has been already shown to stimulate, in rats and humans, the release of 
opioid peptides, such as b-endorphin and enkephalins (Dai et al., 2005; Marinelli et 
al., 2005), contributing to the reinforcing effects of EtOH, and also DYN (Marinelli 
et al., 2006), this last neuropeptide exerting compensatory alterations. 
In this respect, the aversive role of k-opioid agonists is well known (Land et al., 
2008). In the AM, the increased activity of the dynorphinergic system has also been 
observed in dependent animals (5D group), where KOP mRNA resulted up-regulated 
and PDYN gene expression returns to levels comparable with control. Moreover, 
PDYN gene expression resulted to be increased in the AM in the early withdrawal 
(EW) group. Our data are consistent with the hypothesis that the blockage of KOP 
induces a decrease in EtOH intake in rats that are physiologically dependent on 
EtOH, but not in nondependent rats (Walker and Koob, 2008). 
DYN system changes during dependence and in EW are consistent with the 
previously suggested recruitment of this system during the different neurochemical 
and behavioural phases of alcohol intake history (Walker et al., 2010).  
Overall, these effects are here probably linked to the negative dysphoric state in 
withdrawal, that EtOH could relieve as previously proposed (Walker and Koob, 
2008). This is a transient initial effect, because in the next withdrawal interval, up to 
Day 7, no alteration in the gene expression of the precursor was observed. 
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Changes in PNOC/NOP system gene expression 
 
We did not observe any alteration in NOP mRNA levels in both the brain regions 
investigated. In contrast, the PNOC gene expression was increased by EtOH 
administration both after 1 day (1D) as well as in dependent (5D group) and in EW 
group animals in the AM, a key region in regulating alcohol consumption (Koob, 
2003).  
Intracerebro-ventricular injection of NOC as well as administration of NOC into the 
central AM significantly inhibited EtOH self-administration in the alcohol preferring 
animals (Economidou et al., 2008). 
In the central AM of EtOH-dependent rats, an enhanced sensitivity to NOC effects 
was found because the peptide blocked the EtOH-induced augmentation of inhibitory 
postsynaptic currents (Roberto and Siggins, 2006).  
An important role of the NOC system in neuronal circuits involved in reinforcing or 
conditioning effects of EtOH was also proposed by behavioral data (Kuzmin et al., 
2007). 
Thus, our findings, showing a constant upregulation of PNOC gene expression in the 
AM during EtOH intake and, to a lesser extent, in EW, appear to be consistent with a 
role of functional antagonism played by this system (Mogil and Pasternak, 2001) 
towards the positive reinforcing actions of EtOH associated with mu-acting opioids. 
 
 
5.1.2 Epigenetic studies 
 
We here studied the involvement of epigenetic mechanisms in the recently observed 
changes on PDYN and PNOC genes expression evoked by different EtOH 
administrations (D’Addario et al., 2011b). We observed a close relationship between 
selective chromatin modifications and PDYN and PNOC genes expression, 
especially  in rats treated for 1 day with alcohol (1D group). 
Epigenetic mechanisms have already been proposed to be responsible for the cellular 
actions of EtOH (Shukla and Aroor, 2006; Kim and Shukla, 2006) and recently 
chromatin remodeling was suggested to be a plausible characteristic of alcoholism 
(Pandey et al., 2008). 
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It has been observed that chronic EtOH exposure causes a more open structure of 
chromatin, consistent with a switch from heterochromatin to euchromatin (Mahadev 
and Vemuri, 1998).  
In rat hepatocytes, EtOH induced a selective, post-translational acetylation of H3K9 
in a dose-dependent and time-dependent manner (Park et al., 2003), and distinct 
methylation patterns in histone H3K4 and H3K9 correlate with up- and down-
regulation of genes (Pal-Bhadra et al., 2007).  
Our study revealed an inverse relationship of H3K27me3, a repressive mark, and 
H3K9Ac, activating mark, in both PDYN and PNOC promoters, in animals treated 
for 1 day with EtOH in the AM.  
This may point to a covalently modified chromatin domain, already observed by us 
for the PDYN gene in SH-SY5Y cells exposed to alcohol and acetaldehyde 
(D’Addario et al., 2011a) and characterized for many other genes (Azuara et al., 
2006; Roh et al., 2006; Pan et al., 2007; Mikkelsen et al., 2007; Zhao et al., 2007). 
Alterations of H3K9Ac, but not of H3K27me3, were still present in the 5D group for 
the PNOC promoter, again in accordance with the gene expression increase. 
None of the histone modifications under study were not directly associated with gene 
expression changes in the W-1D group.  
This could be possibly explained by different hypothesis. First of all, it has to be 
taken under consideration the complexity of gene regulation by histone modifications 
(Barski et al., 2007) and that multiple modifications may function cooperatively to 
prepare chromatin for transcriptional activation. Moreover, in addition to epigenetic 
mechanisms, gene expression is also regulated by many components of the complex 
transcriptional machinery.  
One possibility for PNOC gene could be also that a long-term maintenance of 
epigenetic chromatin state (Boggs et al., 2002; Peters et al., 2002) could determine 
accessibility for transcription factors eventually inducing specific transcription even 
in absence of the modification not needed anymore.  
 
Changes in DNA methylation in the promoter region of different genes such as the 
alpha-synuclein (Bönsch et al., 2005), dopamine transporter (Hillemacher et al., 
2009), homocysteine-induced endoplasmic reticulum protein genes (Bleich et al., 
2006), as well as PDYN (Taqi et al., 2011) have recently been observed in alcohol 
dependent patients. 
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However, in our study no significant alterations in DNA methylation following 
different alcohol exposures were present.  
This data is anyhow in agreement with our previous in vitro observation showing no 
changes in DNA methylation of PDYN promoter in SH-SY5Y exposed to alcohol 
(D’Addario et al., 2011a). Moreover, we did not observe any alteration of H3K4me3 
in all the experimental groups under study, and thus the latter findings suggest  the 
selectivity of alcohol effects. 
 
 
Overall our data indicate a linkage between gene expression alterations and 
epigenetic modulation in PDYN and PNOC promoters following 1 day and up to 5 
days of alcohol treatment and we observed a cross-regulation of histone 
modifications in the 1D group.  
In our experimental conditions even we did not observed any epigenetic alteration in 
the promoter regions of the genes investigated during withdrawal, we could confirm 
the possible chromatin remodeling mechanism already proposed for alcoholism 
(Pandey et al., 2008). 
 
 
 
5.2 HEROIN 
 
 
5.2.1  Proteins level studies 
 
 
One of the key intracellular pathways activated by MOR is the MAPK pathway. To 
determine whether there are perturbations in protein levels of the MAPK pathway as 
a consequence of chronic heroin abuse, we focused on the core components of the 
pathway including MEK1/2 and ERK1/2.  
In this context, chronic morphine exposure in rats resulted in structural changes of 
neurons compatible with the induction of synaptic plasticity (Sklair-Tavron et al., 
1996; Robinson and Kolb, 1999; Spiga et al., 2003; Liao et al., 2005; Ballesteros-
Yáñez et al., 2007). 
Although some signaling pathways have been associated with morphine-induced 
changes in neuronal size, synaptic connectivity and behavioral plasticity, increasing 
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evidences indicate that proteins of the apoptotic pathways can also play relevant 
roles in promoting various forms of synaptic plasticity (Gilman and Mattson, 2002; 
Mattson and Gleichmann, 2005; Mattson, 2007). 
In the putamen of heroin addicts, the protein expression of MEK1 was significantly 
reduced and on the two known targets of the MEK1/2, we observe an opposite 
effects: significant decrease in the protein level of ERK1 but, conversely, a 
significant increase in the protein levels of ERK2. 
The activation of ERK1 is mediated by both MAPK1/2 and the decrease that we 
observed is clearly evoked by MEK1 level reduction. Conversely ERK2 activation is 
mediated only by MEK2, that didn’t change in our experimental condition, and is 
also be under negative regulation by ERK1, which can inhibit its activation. 
The reduction of the levels of ERK1 protein may lead to a reduction of the block that 
this exerts on the protein ERK2. In this way the effect of a prolonged exposure to 
heroin means, upstream, with a reduction of the activity of MEK1 which has the 
effect downstream to increase the levels of ERK2. 
The control that ERK2 exerts on the protein ELK1 is positive, but the direct effect,  
observed in the putamen of heroin addicts, is a significantly increased in the global 
level of ELK1 but a significant reduction in the level of phosphorylated Elk-1 form. 
Previous studies have shown that amphetamine activates extracellular signal-
regulated kinase 1 and 2 (ERK1/2) resulting in cAMP response element-binding 
protein (CREB) and Elk-1 phosphorylation in striatal neurons (Choe and Wang, 
2002) and our data support the hypothesis that prolonged exposure to substance 
abuse causes a dysregulation of the MAPK pathway in the areas delegated to the 
reward. 
In fact, the striatum is essential for motivation and drug reinforcement. Moreover, 
several basal ganglia dysfunction occurs in drug addiction and its alteration have 
been suggested to be responsible for enhanced liability to abuse drugs 
(Spreckelmeyer et al., 2011). 
The opposite direction in the levels of ELK1 and pELK1 remains controversial. 
Under normal conditions we can expect that the levels of total protein and its 
phosphorylated form going in the same direction after drugs exposure. Often, 
however, the opposite happens. Seems that the direct effect of ERK2 activation been 
the increase in ELK1 total level; the subsequent reduction observed in its 
phosphorylated form could be due to a compensatory effect induced by prolonged 
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activation of the transcription factor, or may simply result from the fact that, even if 
they are fresh-frozen tissue, the time is not sufficient to observe the up-regulation of 
the active form. This is possible if we consider that the exposure to drugs of abuse 
results in adaptation in the brain involving changes in gene expression and 
transcription factors ( Martín et al., 2011). 
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6. CONCLUSION AND PERSPECTIVES 
 
Over the last decade, the distinct processes of addiction  to drugs of abuse are being 
investigated as specific forms of drug-induced neural plasticity, and much attention 
has been focused on the genetic, cellular, molecular and behavioral mechanisms 
underlying the induced changes in brain function (Kalivas and O’Brien, 2008;  
Thomas et al., 2008). Thus, opiate addiction in humans can be approached as a form 
of neuroplasticity, in which the lasting and aberrant adaptations in the brain would 
play major roles in the development of the principal features of this chronic medical 
disorder: opiate tolerance and dependence, behavioral sensitization, and compulsive 
drug use that underlines the long persistence of relapse risk in the addicted person 
(Hyman, 2005; Christie, 2008). 
 
 
Conclusion I 
 
The data about alcohol exposure confirm a role of the PDYN/KOP system in the 
negative hedonic state associated with alcohol addiction (Walker and Koob, 2008) 
and the hypothesis that the NOC system could function as a ‘brake’ to limit EtOH 
intake (Roberto and Siggins, 2006).  
The linkage between gene expression alterations and epigenetic modulation in 
PDYN and PNOC promoters following alcohol treatment confirm the possible 
chromatin remodeling mechanism already proposed for alcoholism (Pandey et al., 
2008). 
Our results could be important to partially fill the lack of knowledge of how EtOH by 
itself affects the opioid system in the brain, and suggest the possibility of using drugs 
acting on these systems for the treatment of withdrawal symptoms and alcohol 
dependence (Walker and Koob, 2008). 
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Conclusion II 
 
The data, about heroin exposure, confirm the presences of perturbations in protein 
levels of the MAPK pathway as a consequence of chronic heroin abuse. 
Moreover, we have shown that the activation of extracellular signal-regulated kinase 
1 and 2 (ERK1/2) resulting in Elk-1 phosphorylation in striatal neurons (Choe and 
Wang, 2002) supporting the hypothesis that prolonged exposure to substance abuse 
causes a dysregulation of MAPK pathway, in the areas delegated to the reward. 
Our results could be important to clarify the role of ELK1 in the regulation of several 
gene expression, for changes in neuronal size, in the synaptic connectivity and in 
behavioral plasticity (Gilman and Mattson, 2002; Mattson and Gleichmann, 2005; 
Mattson, 2007). 
 
 
 
 
 
Knowledge of the neuroanatomy, neurophysiology, neurochemistry and 
neuropharmacology of addictive drug action in the brain is currently producing a 
variety of strategies for pharmacotherapeutic treatment of drug addiction, some of 
which appear promising. 
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